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3 Motivation 
The ‘metabolome’ 1 represents the nonstructural molecular phenotype of a 
cell, tissue or organism. It comprises a great number of compounds of low 
molecular mass (typically <1,000 Da), which differ greatly in their chemical and 
physical properties.2 Metabolomics denotes the comprehensive and quanti-
tative analysis of all the small molecules present in the system. However, to 
date no single method has been described that is suitable for an exhaustive 
metabolomic analysis.2 One strategy to circumvent this problem is the 
integration of different methods into a comprehensive analysis platform. Most 
methods for metabolome analysis either aim at the accurate quantification of a 
selected subset of metabolites or at the general profiling of a great number of 
compounds with very limited information on abundances. Another important 
prerequisite in metabolomics is the capability to measure a high number of 
samples in a reasonable amount of time, in order to account for biological and 
analytical variability. For this purpose, it is not practicable to analyze one 
sample with many different methods. The integration of these general condi-
tions points to a substantial need for methods that integrate several analytical 
aspects. Examples are the combined analysis of different metabolite classes 
(e.g. amino acids and fatty acids), the combination of accurate quantification 
with screening (see Aim # 1) or the integration of highly sensitive quantification 
with structural information (see Aim # 3). 
Aim # 1: Development of a method that combines accurate quantification 
of metabolites of the central carbon metabolism with screening for 
unknowns 
One major goal of the present work was the development of a method that 
would allow both the absolute quantitation of selected metabolites and the 
semiquantitative screening for unknown analytes and their identification with 
high confidence. The initial focus was on the analysis of the central carbon 
metabolism, an important node for the energy metabolism of a cell that 
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generates many precursors for diverse cellular functions, such as amino acids 
and nucleotides (Figure 1). The metabolites involved in the corresponding 
pathways are mostly negatively charged, and many are phosphorylated. 
These small, hydrophilic molecules are not well suited for reversed-phase 
liquid chromatography – mass spectrometry (RP-LC-MS) analysis.3-5 On the 
other hand, gas chromatography (GC), which is the method of choice for many 
global metabolome studies,6-9 requires pre-column derivatization and is not 
applicable to the quantitation of thermally instable compounds, such as 
phosphorylated metabolites.  
Therefore, capillary electrophoresis (CE) was chosen for the separation of the 
charged metabolites, because it yields narrow peaks and has a high separa-
tion efficiency for isobaric compounds such as hexose-phosphates.10 A time-
of-flight mass spectrometer (TOF-MS) was used for analysis, because it pro-
vides a wide dynamic range for absolute quantification and high mass accu-
racy and fast scan speed over a wide mass range, which are prerequisites for 
screening applications. The CE-TOF-MS method was optimized with regard to 
the separation of metabolically important isobars, e.g. hexose-phosphates and 
glycerol-phosphates, method stability and robust quantification. Method 
parameters such as limit of detection (LOD), limits of quantification (LOQ), 
linear range and reproducibilities were established. 
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Figure 1: Schematics of the central carbon metabolism. Arrows denote the respective amino 
acids that are built from the indicated precursors. 
 
 
 4
Aim # 2: Application of CE-TOF-MS to the metabolome analysis of E. coli 
The CE-TOF-MS method was applied to the metabolomic analysis of the 
model organism Escherichia coli. To that end, several sample preparation 
steps had to be optimized, including cell harvesting, extraction of metabolites, 
and the evaluation of matrix effects during CE-MS analysis. The method was 
then applied to the analysis of two different E. coli strains that differ in 
glycolytic flux distribution. We quantitated a selected subset of central carbon 
metabolites and identified many more compounds. We adapted programs for 
peak detection and alignment to our specific needs and compared their 
performance with data from the absolute quantification. Furthermore, we 
introduced several measures to ascertain the identity of every analyte. Finally, 
the semi-quantitative information from the high-confidence identification of 
additional metabolites was integrated with the data on absolute levels of 
selected metabolites and, thus, we were able to obtain a comprehensive 
picture of metabolic differences between the two E. coli strains studied. 
Aim # 3: Development of a method that combines sensitive 
quantification with structural information 
The CE-TOF-MS method was well suited for the application described above. 
However, it lacked robustness for the study of large sample batches and its 
detection limits were mostly in the low micromolar range. These 
considerations prompted us to develop a method that allowed for the robust 
quantification of target analytes with low limits of detection, yet also yielded 
information on molecular structure. We chose ion-pair liquid chromatography, 
which had been shown to yield good separation of negatively charged me-
tabolites.11 The LC column was directly coupled to a triple quadrupole ion trap 
mass spectrometer operated in single reaction monitoring (SRM) mode.  
In order to reduce analysis time, a rapid resolution HPLC system on sub-2μm 
octadecyl silica partiles was implemented. Initially, the method was tailored for 
the rapid quantitative measurement of lactate and pyruvate. Later the method 
was expanded to a panel of metabolites representing both the upper (glycoly-
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sis, PPP, methylglyoxal pathway) and the lower part (TCA, glyoxylate shunt) of 
the central carbon metabolism. 
Aim # 4: A simple and rapid method for flux analysis in E. coli and 
human cells 
Measuring metabolite concentrations yields interesting information on biologi-
cal systems. However, in order to access knowledge on perturbation in intra-
cellular fluxes, the fate of labeled precursors has to be monitored. The appli-
cability of the optimized RR-IP-LC-MS/MS method for flux analysis was 
therefore evaluated. Alterations in fluxes of the central carbon metabolism 
were monitored by the conversion of [1,2-13C2]glucose to lactate and other 
intermediates of important metabolic pathways. Again E. coli was used as a 
model organism. In an initial proof-of-principle study, we measured changes in 
the ratio of glycolysis to pentose phosphate pathway (PPP) in a wild type vs. a 
mutant E. coli strain to confirm that our method would match results obtained 
previously by gas chromatography-mass spectrometry.12 In a next step we 
evaluated the suitability of this strategy for the analysis of other fluxes, such as 
the citric acid cycle (TCA) and the glyoxylate shunt. Finally, the method was 
extended to human immune cells to elucidate the effect of high extracellular 
amounts of lactate, which are found in certain tumors, on immune cell function. 
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4 Background 
An abbreviated version of this chapter was published in Analytical 
Bioanalytical Chemistry.13 
4.1 Metabolomics 
The complete set of small molecules synthesized by an organism, termed 
metabolome, 1 closest reflects the actual nonstructural phenotype and, thus, 
the effective behavior of the cellular system of interest (Figure 2). 
 
Figure 2: The ‘Omics’ cascade – Information flow in a cell. Adapted from 2 
The metabolite levels are constantly influenced by enzymatic reactions 
catalyzed by proteins, which themselves are highly regulated by transcriptional 
and translational control and by interactions with other proteins and metabo-
lites. One can therefore expect that the measurement of global metabolite 
levels will reflect the actual state of a certain biological system under defined 
circumstances. However, the term ‘metabolome’ comprises a great number of 
compounds (e.g. an estimated number of > 200,000 in the plant kingdom 14) 
that share the property of a low molecular mass (usually < 1,000 Da) but differ 
 7
in many other chemical and physical properties. So far, there exists no single 
method to identify and quantify all of them.2  
Different strategies have emerged for tackling the complex data space of the 
metabolome. However, they differ in their demand on prior knowledge about 
the analytes of interest, and also require methods with different capabilities for 
the identification and quantification of the analytes.2, 15, 16 
Metabolic profiling focuses on groups of metabolites that are selected by 
their relation to a specific metabolic pathway, their compound class or some 
other shared property. This allows the analysis to be tailored to the specific 
features of these metabolites. Usually, the focus during method development 
is on robust quantification and specificity. This approach is very useful for 
hypothesis-testing and adressing well-defined biological questions. 
Target analysis is even more directed than metabolic profiling and only very 
few analytes are measured. They are often directly related to a genetic pertur-
bation, such as substrates or products of enzymatic reactions, or they serve as 
biomarkers for a certain disease.17 
However, these approaches are not truly ‘omic’ in the sense of yielding a 
global picture of the metabolic state of the system of interest. Prior knowledge 
about the nature of the analytes is required and all information on metabolites 
not specifically included in the analysis is lost. 
Metabolic fingerprinting, on the contrary, aims at the detection of as many 
analytes as possible. Initially, the focus of this approach was mainly on the 
detection of patterns, the so called “fingerprints”, that were caused by pertur-
bations in the metabolism, such as mutations, disease or exposure to chemo-
therapeutics or toxins (Figure 3). 
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Figure 3: Simplified workflow for a metabolic fingerprinting analysis. Taken from 2 
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The reasoning is, that those patterns can later be used as markers for these 
perturbations, without immediate need for the identification of its constituents. 
However, information on the metabolites that are altered under certain 
conditions is likely to elucidate the mechanism underlying the perturbation. 
Therefore, it will be necessary to develop screening methods that yield a high 
amount of additional information on the detected compounds, such as 
accurate mass, isotopic pattern, structural information and other physical or 
chemical properties. 
A drawback of this approach is the relative quantification of peaks between 
different samples, i.e. no absolute concentrations are determined. It is thus 
very important to implement quality control steps and randomization to prevent 
wrong conclusions caused by changes in instrument and sample stability. 
Metabolic footprinting uses the same methods as fingerprinting but is limited 
to the analysis of metabolites in cell culture media. The reasoning is, that 
compounds excreted by a cell or taken up from the medium will also give 
valuable insights into a cell’s phenotype and physiological state.18 A major 
advantage is, that samples can be analyzed directly without the need for 
quenching, i.e. the rapid stop of enzymatic acitivity, which often introduces 
additional variation or bias, as discussed in chapter 4.4. 
4.2 Detection methods for metabolomics 
The ultimate goal of metabolomics is the comprehensive analysis of all small 
molecules in a given system. Even though elaborate separation methods are 
usually employed, the use of a detector that can provide additional information 
on each detected compound is of high value. The detection methods mainly 
used for metabolomics are mass spectrometry and NMR. Mass spectrometry 
yields information on the amount of analyte present, its mass and its structure, 
depending on the type of mass analyzer used. NMR also produces 
quantitative data and is an excellent tool for structure elucidation. 
 10
4.2.1 Mass spectrometry 
Mass spectrometry is commonly used in metabolomic studies due to its high 
sensitivity and throughput and the ability to confirm or even establish the 
identity of the detected compounds. Today, a number of different types of 
mass spectrometers are on the market and it is very important to understand 
their power and limitations in order to choose the best detector for the problem 
at hand. 
Time-of-Flight (TOF) 
This detector is based on the observation, that the time ions need to travel a 
fixed distance depends on their m/z ratio when accelerated with the same 
amount of energy (Figure 4).  
 
Figure 4: Schematics of a TOF-MS with reflectron (from 19) 
Modern TOF instruments are equipped with a curved-field reflectron in the 
flight tube, which corrects for initial differences in kinetic energy.20 The newest 
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generation of TOF instruments contains an analog-to-digital converter (ADC) 
that provides linearity over four orders of magnitude. This is due to the fact 
that the ADC records the total signal strength at a very high rate (1-4 GHz) as 
compared to the previously used time-to-digital converter (TDC), which 
measured the exact arrival time of the first ion of a given mass.21 
The advantages of the TOF-MS are its high scan speed, making it the fastest 
MS analyzer available. Also, it has the highest practical mass range of all 
analyzers, which is, however, limited if a reflectron is used.22 The new 
generation of TOF instruments achieves a very high mass accuracy (down to 
3-5 ppm), which makes it very suitable for screening purposes, because iden-
tification is more specific.23 The wide linear range allows the accurate 
quantification of isotope peaks. The combination of accurate mass and exact 
quantification of isotope distributions is used for theoretical molecular formula 
generation,24 which is useful in the identification of unknown compounds. The 
main limitation of the TOF analyzer is its higher detection limits in comparison 
to a triple quadrupole instrument, because no precursor selection and, thus, 
background reduction can be performed. In addition, the instrument is sensi-
tive to temperature changes and in order to achieve the highest mass 
accuracies, re-calibration with a standard mix is required regularly. 
Quadrupole instruments  
A quadrupole ion filter consists of four parallel rods. The rods have a fixed DC 
(direct current) and alternating RF (radio-frequency) voltages applied to them. 
Depending on the produced electric field, only ions of a particular m/z will be 
allowed to pass, all the other ions will be deflected into the rods. 
The quadrupole ion filter is the most common mass analyzer and is used in 
routine analysis, for which it is well suited because of its good reproducibility 
and excellent stability.22 One disadvantage of the quadrupole analyzer is its 
unit mass resolution. For that reason, it is not well suited for identification of 
unknowns. Its mass range is limited; it is able to analyze ions up to an m/z 
ratio of about 3,000-4,000. It has been used in metabolomics, albeit multiple 
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analyses had to be performed on each sample to cover the entire mass range 
with sufficient sensitivity.25 
In triple quadrupole (TQ) instruments, three quadrupoles are combined 
sequentially. The second quadrupole (Q2) functions as a collision cell, where 
analytes selected in Q1 are fragmented. These fragments are selected in Q3 
and analyzed. Several modes of tandem mass spectrometry (MS/MS) are 
available (Figure 5). The TQ is the instrument of choice if robust and sensitive 
quantification is required.26 Also some information on molecular structure can 
be gained from product ion scans. 
 
Figure 5: Scan modes in a TQ instrument (from 27). 
Quadrupolar or 3D ion trap 
The ion trap (IT) consists of a ring electrode and two endcap electrodes. An 
AC potential of constant frequency and variable amplitude is applied to the 
ring electrode to produce a 3D quadrupolar potential field within the trapping 
cavity, which traps ions in a stable oscillating trajectory. During detection, the 
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electrode system potentials are altered to produce instabilities in the ion 
trajectories and thus eject the ions according to their m/z ratio in axial 
direction.  
The advantages of the ion trap are its high sensitivity due to accumulation of 
ions within the trap and the provision of multiple sequential MS/MS experi-
ments (MSn) that facilitate structure elucidation of larger molecules, e.g. 
peptide sequences. The limitations of the ion trap are poor quantitation, low 
mass accuracy and a poor dynamic range. The trapped ions are subject to 
space charge effects and ion molecule reactions, thereby complicating data 
analysis.28 
Linear ion trap 
The linear ion trap (LIT) has a design similar to a quadrupole mass analyzer, 
with the addition that a static electrical potential can be applied on end elec-
trodes to confine the ions axially. Compared to 3D-ion traps, the LIT has 
higher injection efficiencies and higher ion storage capacities.29 It is often com-
bined with other mass analyzers in hybrid instruments, as discussed in the 
next paragraphs. The LIT is mostly used for applications demanding low 
detection limits and great robustness, and for MS/MS and MSn 
characterization.30, 31 A dynamic range of up to five orders of magnitude with a 
detection limit of ~10zmol (~6000 molecules) has been reported.32 
Fourier-transform ion cyclotron resonance mass spectrometer (FT-ICR) 
In this type of mass analyzer, ions are trapped in a stable orbit in an electro-
magnetic field. A resonant radio frequency (RF) signal is used to excite the 
orbiting ions and as a result the ions produce a detectable image current. By a 
short RF impuls all ions with different m/z ratios are excited simultaneously 
and the evolution of the resulting signal in time is recorded. Numerical trans-
formation from the time to the frequency domain, the so-called “Fourier trans-
formation”, provides a conventional spectrum. Due to the general ease to pre-
cisely measure frequencies, very high mass resolutions are achieved.33 High 
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mass accuracies aid in the identification of unknown compounds, however it 
was shown that for larger molecules, additional information on isotope 
patterns is very important for reliable identification.23 In addition, ion excitation 
can be used for MS/MS and MSn experiments or for selective ion ejection.33 
The limitations of FT-ICR are for one its limited dynamic range. Additionally, 
the mass spectrum is complicated by space charge effects and ion molecule 
reactions during ion storage and artefacts such as harmonics and sidebands. 
The handling of the FT-ICR is rather complex and it is very expensive in 
acquisition and maintenance. 
Triple quadrupole – linear ion trap (QTRAP) 
The QTRAP is essentially a triple quadrupole instrument, where the third 
quadrupole can also be used as a LIT. Its advantage in comparison to the TQ 
is the high sensitivity in scan mode, due to ion accumulation by trapping. Also, 
MSn can be performed when the trap function is activated. The QTRAP is 
often used in MRM mode for the robust quantification of compounds, where 
very low limits of detection can be achieved.11 In a successive experiment, the 
same sample can be analyzed in trap mode and thus screened for additional 
analytes of interest. In addition, high-sensitivity product ion scans can be used 
as an identification tool by investigating characteristic fragmentation patterns. 
Quadrupole time-of-flight (QTOF) 
The QTOF is a combination of two quadrupoles with a TOF mass analyzer, 
which will scan all the ions emerging from the collision cell. The Q1 can be 
used as a mass filter to substantially reduce background noise and, thus, 
achieve higher sensitivity. On the other hand, the TOF can be used to acquire 
a full product ion spectrum of the selected and fragmented ion or it can be 
used for screening. The advantage of this hybrid instrument type over a nor-
mal TOF is its ability to provide accurate mass measurements together with 
structural information.26, 34 As a consequence, however, detection limits are 
not as low as in TQ-MS.35  
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4.2.2 Nuclear magnetic resonance spectroscopy (NMR) 
Atomic nuclei with non-zero spin adopt quantized orientations in magnetic 
fields. Transitions between these quantized states can be induced by radiofre-
quency irradiation. The transition energies are dependent on the type of the 
atom and they are additionally modulated by the electronic environment of 
each respective nucleus, which is the origin of the different chemical shift 
values of atoms occurring in different molecular positions.36 Analysis by NMR 
is based on (i) the modulation of the resonance energy by the electronic 
enivonment of a given atomic nucleus and (ii) the mutual influence that 
neighbouring nuclei exert on each other via chemical bonds (scalar coupling) 
and/or by interaction through space (nuclear Overhauser effect, NOE).36 
The advantages of NMR are its capability for the structural characterization of 
unknown compounds and its robust quantification, at least in 1D-NMR.37 How-
ever, its requirement for large sample volumes adversely affects sensitivity. 
LODs are under optimal conditions in the high nanomolar to low micromolar 
range for small molecules. Yet they depend very much on the spectral back-
ground, the solvent and the sample matrix.38 The linear dynamic range of con-
ventional instruments is roughly three orders of magnitude. Moreover, certain 
method parameters such as intersample peak position and line width are very 
sensitive to the chemical environment of the sample (e.g. pH, ion strength, 
etc.) and external factors such as tempterature.39 
There are numerous applications for NMR in metabolic analyses. It is often 
used for structure elucidation of complex secondary plant metabolites.36 NMR 
is also used for pathway elucidation, where the fate of isotope tracers is 
monitored.36 Most metabolomics studies to date use NMR for metabolite 
profiling without absolute quantification. NMR has been used to investigate the 
effects of gender, diurnal variation and age in human urinary samples. Accu-
racy and precision from the measurement by three analysts was evaluated.37 
Several studies using NMR for nutritional applications are reviewed in.39  
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Figure 6: (a) One-dimensional 1H NMR spectrum of an equimolar mixture of the 26 small-
molecule standards listed in Supporting Information Table 1. (b) Two-dimensional 1H-13C 
HSQC NMR spectra of the same synthetic mixture (red) overlaid onto a spectrum of aqueous 
whole-plant extract from A. thaliana (blue). Provided by 38. 
Quantification of complex biological samples by NMR is still in its infancy. The 
problem with analyzing complex spectra is the fact that overlapping peaks do 
not scale in the discrete linear fashion that typifies well-isolated peaks.38 This 
impediment can be circumvented by applying two-dimensional (2D) 1H-13C 
NMR strategies (Figure 6). However, in this approach cross-peak intensities 
are influenced by a greater number of variables, such as uneven excitation, 
 17
nonuniform relaxation, varying J-coupling values etc. Nevertheless, it was 
shown that 2D-NMR leads to superior quantification of complex samples over 
a concentration range of 1 – 30 mM. Metabolites from different organisms, e.g. 
A. thaliana and S. cerevisiae, were quantified by this approach.38 The 
quantitative capabilities of a “targeted profiling” approach were evaluated by 
measuring simplified synthetic urine. It was found that this method is highly 
stable in PCA-based pattern recognition, insensitive to water suppression, 
relaxation times and scaling factors. Also, it was validated against various 
metabolites at physiological concentrations (9 μM – 8 mM).40 
4.3 Methods for metabolome analysis 
4.3.1 Direct infusion 
Direct injection of samples into mass spectrometers without any prior separa-
tion of analytes provides rapid, high-throughput analysis of crude samples or 
sample extracts. It is most often used with ESI-MS analysis, where the sample 
is delivered to the mass spectrometer at low μL/min flow rates. Usually, a 
high-resolution mass detector, such as a TOF-MS or a FTICR-MS is used,2 
because the only molecular feature for analyte identification is its mass. Thus, 
the higher the mass accuracy for the measurement of the metabolite of inter-
est, the more reliable its identification will be. An alternative is using fragmen-
tation patterns derived from MS/MS analysis. Obvious limitations of this 
approach are that it is (i) not able to discriminate between isobaric metabolites 
and (ii) matrix effects are likely to impede quantification and identification, e.g. 
by adduct formation and ion suppression.41 Nevertheless, its suitability for very 
high-throughput analyses makes it an interesting tool in medical screening. To 
date the most important application of this approach is the screening for inborn 
errors of metabolism, especially for newborn screening. Also, the rapid 
profiling of secondary metabolites in plants and fungi has been described.15  
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4.3.2 Matrix-assisted laser desoption/ionization – mass 
spectrometry (MALDI-MS) 
MALDI-MS is commonly used in proteomics. It has not been used until 
recently for the analysis of small molecules. This is mainly due to the strong 
interference from matrix ions in the low molecular weight range (< 500 m/z). In 
addition, the conventional matrices are much more suitable for ionization in 
positive mode, which is not feasible for small organic acids and phosphory-
lated compounds, which constitute some of the most important metabolites. 
The introduction of 9-aminoacridine (9-AA) as a matrix has been shown to 
yield low background and high sensitivity in negative mode.42, 43 9-AA was 
used for the analysis of metabolites in E. coli and islets of Langerhans by 
MALDI-TOF-MS.44 LODs were between 15 nM and 1 μM. In E. coli, 60 
metabolites were detected, 39 of which matched compounds in the MetaCyc 
database. Reproducibilities (RSD) for repeated measurements of one sample 
were acceptable with 8-12%. However, inter- sample reproducibility was worse 
(46-73%). A linear response for spiking one analyte into a metabolite mixture 
was seen over one order of magnitude. However, linearity was not good (0.94-
0.988) and reproducibility of replicate measurements was rather poor (often > 
100%).45 To assess the quantitative capabilities of MALDI-MS in more detail, a 
metabolite cocktail was spiked with different concentrations of single metabo-
lites.46 The variations for replicate measurements were again rather high, 
which the authors contributed to the heterogeneity of analyte distribution on 
the surface. Nevertheless, it was clearly seen that changes in the concentra-
tion of one analyte often influenced the quantification of other metabolites. A 
correlation between chemical similarity and degree of influence was clearly 
established. These findings demonstrated the limited utility of MALDI-MS for 
quantitative analysis. 
4.3.3 Capillary electrophoresis 
In capillary zone electrophoresis (CZE) analytes are separated according to 
their mobility in an electric field. The mobility is influenced by the ion radius, 
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the charge of the molecule and the viscosity of the solution (1). The electro-
phoretic mobility is denoted as μp, the charge of the analyte as z, viscosity of 
the solution as η and r stands for the ion radius. 
        (1) 
The effective mobility in a given system is in addition influenced by the 
electroosmotic flow (EOF). The EOF depends on the chemical nature of the 
capillary wall, as well as on pH and ion strength of the background electrolyte 
(BGE). In capillary electrophoresis, metabolites can be measured directly in 
aqueous solution, eliminating the need for time-consuming sample preparation 
and derivatization steps. Peak capacities in CE are very high, due to the 
narrow peaks caused by the plug flow of the bulk liquid as compared to the 
parabolic flow profile in LC. Another advantage is that only minute amounts of 
sample, usually a few nanoliters, are required for one injection, which is 
important for samples of limited availability, e.g. patient derived samples, and 
permits the re-analysis of samples. However, the small injection volumes can 
also pose a disadvantage, in that they increase detection limits with regard to 
detectable concentrations. Another issue in CE is sample ion strength. While a 
low ion strength can increase resolution by stacking effect, 47, 48 high ion 
strength can lead to peak broadening and alterations in migration behavior. 
A particular challenge in the analysis of intermediates of the central carbon 
metabolism is the presence of isobars such as glucose-6-phosphate (G6P) 
and fructose-6-phosphate (F6P) that also have similar mass spectrometric 
fragmentation patterns. These compounds require electrophoretic or chroma-
tographic separation prior to mass spectrometric detection. Capillary electro-
phoresis has been successfully employed in the separation of isobaric com-
pounds using coated capillaries and a reversed EOF.25 By coupling CE to a 
quadrupole mass analyzer, methods for the analysis of positively and nega-
tively charged central carbon metabolites and associated nucleotides were 
developed. With this method combination, more than 1,600 potential metabo-
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lites were detected in B. subtilis.10 However, the main disadvantage of this 
approach was the need for multiple analyses of each sample, because narrow 
m/z windows had to be analyzed in order to screen for unknown metabolites 
with high sensitivities. 
Therefore, the coupling of CE to a time-of-flight (TOF) MS was introduced.49 
This allows for the scanning of the complete mass range of small molecules, 
e.g. 50 – 1000 m/z, several times per second and, thus, the detection of a 
great number of features that represent potential metabolites. The method 
was applied to the analysis of oxidative stress in liver cells and 1,859 peaks 
could be detected in mouse liver extracts. Comparative quantitative analysis 
between normal cells and liver cells that were oxidatively stressed by 
acetaminophen revealed multiple changes in metabolite levels, including the 
activation of the ophthalmate biosynthesis pathway.  
The application of CE coupled to a triple quadrupole mass analyzer has not 
been demonstrated yet for the study of the central carbon metabolism, but its 
general utility has been demonstrated for the quantitative analysis of amino 
acids in human urine.50 Highly selective multiple-reaction monitoring (MRM) in 
positive ion mode was used to quantify 32 free amino acids. LODs ranged 
between 0.1 and 14 μM, the calibration was linear between 10 – 200 μM. 
Apparently, the relatively high LODs are mainly due to the small volumes 
injected in CE. 
4.3.4 Liquid chromatography 
Reverse-phase (RP) LC is usually the method of choice for direct coupling to a 
mass spectrometer. It is robust, yields stable retention times and uses sol-
vents that are highly compatible with ESI-MS. However, many important me-
tabolites are highly polar or even charged and, therefore, do not interact with 
the hydrophobic alkyl chains of a RP surface. Different approaches were sug-
gested to overcome this problem, with the most promising being ion-pair liquid 
chromatography (IP-LC) and hydrophilic interaction chromatography (HILIC). 
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4.3.4.1 Reversed-phase liquid chromatography 
Recently, RP-LC has been used in metabolomics following the introduction of 
modifications that served to increase the otherwise poor resolution of polar 
metabolites. Analysis of polar analytes in RP-mode often requires starting the 
LC-gradient with 100% water to achieve analyte retention. However, the 
brush-like structure of conventional C18 phases will collapse under these con-
ditions and analyte retention is impeded. In addition, pore-dewetting occurs, 
which denotes the exclusion of the highly polar solvent from narrow RP-coated 
pores. Moderately polar compounds can be separated on polar- or hydrophilic-
endcapped C18 phases. The endcapping groups allow the silica surface to be 
wetted with water and thus enable the full interaction with the longer alkyl 
chains. Another method to use C18 columns with highly aqueous mobile 
phases is using polar-embedded stationary phases. Due to the incorporation 
of a polar functional group in the alkyl ligand close to the surface of the silica 
gel, the phase remains solvated even at 100% water.51  
One strategy to use RP-LC for small, highly polar molecules is the employ-
ment of alternative stationary phases or support material, such as monolithic 
phases and porous graphitic carbon columns. The advantage of monolithic 
silica capillary columns is their up to 30 times greater permeability as com-
pared to 5-μm particle columns, due to the much higher porosity of the silica 
rod.52 A monolithic RP column of 90 cm length was applied for the analysis of 
the Arabidopsis thaliana metabolome using an ion trap MS in both positive 
and negative mode with continuous polarity switching. Several hundred peaks 
were observed and the high resolution obtained with the long column led to a 
reduction of noise and thus better quantitation. Monolithic columns are often 
used for high-speed separations.53 Especially effective is the direct coupling to 
high-flow on-line extraction. Cycle times, i.e. extraction, separation and analy-
sis, of less than two minutes were achieved by these approaches.54 Another 
interesting development is the use of monolithic columns as the second di-
mension in online 2-D LC-MS separations. The high speed that can be 
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achieved on these columns allows the direct analysis of fractions collected 
from the high-resolution separation employed in the first dimension.55  
Porous graphitic carbon (PGC) stationary phases show high retention of ana-
lytes with high polarity. The retention mechanism is determined by hydropho-
bic eluent-analyte interactions and electronic interactions of polarizable func-
tional groups in the analyte with the delocalized π-electrons of the graphite 
surface.56 They are used for the separation of phosphorylated carbohydrates, 
where high resolution of isomers can be achieved.57 However, they did not 
prove suitable for the separation of nucleotides, which had to be analyzed with 
a different method. Nucleotides and nucleosides were later separated on a 
PGC column after extensive optimization of the LC parameters.58 The use of 
acetonitrile instead of methanol and ammonium acetate and diethylamine as 
modifiers finaly yielded optimal retention and peak shapes. A method for the 
analysis of sugars and sugar phosphates was developed on a PGC column 
coupled to an ion trap MS that achieved good linearity between 1-100 μM with 
LODs of 0.1-1.5 μM.59 However, a complex gradient with three solvents had to 
be used to separate all analytes in a single run. 
4.3.4.2 Rapid resolution – ultra performance liquid chromatography 
An important goal in metabolomics – and other ‘omics’ approaches – is the 
analysis of as many analytes as possible in a short time. Thus, methods are 
required that yield high peak capacities, i.e. narrow peaks and high resolution. 
From basic chromatographic theory 60 it becomes clear that reducing particle 
size is one means to increase separation efficiency (Figure 7).  
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Figure 7: Van-Deemter Plot for different stationary phase particle sizes. Adapted from Halasz 
et al., 1975. 
The Van Deemter curve for small particles indicates a low influence of the C-
term on H when the flow rate is increased. This enables faster separations 
without loss of efficiency. Reducing the particle size by a factor of 2 doubles 
separation efficiency and, thus, increases the resolution by a factor of 1.4.61 
However, back-pressure is increased by a factor of 8. The introduction of LC 
systems that can generate and tolerate high pressure (600-1000 bar) and 
columns packed with sub-2μm particles led to the rise of commercialized 
approaches termed ultra-performance liquid chromatography (UPLC, Waters), 
and rapid resolution (RR, Agilent).  
To date there exist a number of proof-of-principle studies demonstrating the 
higher peak capacities, increased resolution and/or shorter analysis times of 
UPLC as compared to conventional RP-LC.62, 63 For example, the use of 
UPLC led to an increase in peak capacity by more than 2-fold, an almost 10-
fold increase in speed and 3- to 5-fold lower detection limits as compared to a 
conventional 3.5-μm stationary phase. The number of peaks detected in a 
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typical mouse urine sample was increased from ~2,000 for HPLC-MS to 
~10,000 for UPLC-MS. These features were subsequently used to distinguish 
different mouse populations by principal component analysis (PCA).62 
A thorough comparison of 5, 3.5 and 1.7 μm particles under different condi-
tions was performed by deVilliers et al. 61 Higher optimal velocities (~0.37 
cm/s) and lower minimum plate heights (~4.4 μm) were found for well-retained 
compounds using 1.7-μm particles, as expected from theory. Experimental re-
sults demonstrated that the combination of high optimal flow rates and shorter 
column lengths allowed a gain in speed at constant efficiency by a factor of 
about 4.3 and 3.5 in comparison to 5 and 3.5 μm particles, respectively. 
4.3.4.3 Ion-pair liquid chromatography 
Many of the small molecules that comprise the metabolome are highly polar 
and charged. These compounds are not well suited for reversed-phase LC, 
which is, nevertheless, the method of choice for LC-MS coupling. One way of 
rendering charged analytes amenable to separation under RP conditions is 
the use of ion pair (IP) reagents. Different theories were proposed to describe 
the mechanism of IP-LC.64 Charged hydrophobic species are used as IP-
reagents. These compounds are adsorbed at the interface between the 
stationary and mobile phase, creating a charged surface, while the inorganic 
counterions form a corresponding diffuse layer. This implies that the IP-
reagent creates an electrostatic surface potential, and that the magnitude of 
this potential is primarily determined by the surface concentration of the IP-
reagent (Figure 8/B). Another hypothesis is the generation of uncharged com-
plexes between the IP-reagent and the analyte, which are much less polar and 
will thus be retained on a C18 column, depicted in Figure 8/A.64 The main 
parameters that influence the retention of an analyte in IP-LC are (i) the con-
centration of the IP-reagent in the solvent, (ii) the type of IP-reagent and (iii) 
the ionic strength of the mobile phase.  
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Figure 8: Cartoon illustrations of interactions between cationic solute A+ and bonded silica 
phase according to: (A) “ion pair formation in the mobile phase” and (B) “dynamic ion-ex-
change in the stationary phase” mechanisms in the presence of a mobile phase additive X−C+. 
Taken from 65. 
Different IP reagents have been used in the few studies on metabolome 
analysis reported to date. Hexylamine was used for the separation of nucleo-
tides, coenzyme A and its esters as well as sugar nucleotides and sugar 
bisphosphates.66 A combined methanol and pH gradient was employed for the 
separation. MS/MS analysis was performed on a 4000 QTRAP triple quadru-
pole ion trap MS. Imprecision was lower than 10% and good linearity was 
found over 3 orders of magnitude. LODs (S/N < 3) were between 0.1-1 ng in-
jected on column. The method was applied to E. coli, B. subtilis and L. planta-
rum, with reproducibilities of multiple injections (n=12) below 10%. In another 
study, octylammonium acetate and an acetonitrile gradient were used to re-
solve intermediates of the pentose phosphate pathway (PPP). Phosphorylated 
sugars were measured in bloodspots, fibroblasts and lymphoblasts 67 on an 
API-3000 triple quadrupole MS operated in negative mode. Employing 
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multiple-reaction monitoring (MRM), intra-and inter-assay variation was 
between 3-17% and 5-21%, respectively, for the different biological matrices. 
Detection limits for most sugar phosphates were between 0.1-1 μM.  
Recently, an IP-LC-MS/MS method was developed for the quantitative 
analysis of 29 negatively charged compounds of the central carbon metabo-
lism, employing tributylammonium acetate (TBAA) as the volatile ion pair 
modifier.11 The use of the 4000 QTRAP for monitoring selective MS/MS transi-
tions for each compound resulted in very low LODs, mostly below 60 nM. 
Calibration curves were linear over three orders of magnitude, and relative 
standard deviations for repeated measurements of an E. coli cell extract were 
below 6% for all metabolites.11  
4.3.4.4 Hydrophilic interaction liquid chromatography (HILIC) 
In HILIC the separation of polar compounds is achieved by using a normal-
phase (NP) stationary phase, with a solvent system similar to RP yet with a 
reversed gradient, i.e. from low to high water content. The weak eluent in 
HILIC is the organic solvent, mostly acetonitril, which contains a low 
percentage of water, typically 2.5%. The retention mechanism was suggested 
to involve mostly partitioning between the hydrophobic mobile phase and an 
aqueous layer formed on the stationary phase.68 Therefore, contrary to RP-
LC, unpolar analytes elute first from the HILIC column, while polar analytes 
are retained. The applicability of coupling HILIC to MS was demonstrated.3 
HILIC is also well suited for the separation of polar compounds that do not 
necessarily have to be charged under the separation conditions, such as 
sugars.3 A comprehensive study on HILIC-MS of ~160 commercially available 
metabolites demonstrated its usefulness for diverse compound classes such 
as amino acids, amino acid derivatives, nucleosides, their bases and mono-, 
di- and tri-phosphates as well as CoA and its esters, carbohydrate derivatives 
and precursors, vitamins, carboxylic acids, redox-electron-carriers and others.5 
Of the 141 metabolites amenable to HILIC-MS/MS analysis, 69 could be 
quantified from E. coli extracts and for 39 significant changes were detected 
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upon carbon starvation. The method was subsequently used to investigate the 
metabolomic response to starvation in E. coli and S. cerevisiae.69 The filter-
culture approach used in this study allowed the very rapid quenching of the 
metabolism without risk of leakage (Figure 9). A very striking finding in this 
study was the dynamic range of the metabolite concentration changes upon 
starvation, with some metabolites decreasing or increasing by ~100 times. 
However, the median relative standard deviation of repeated analysis of the 
same extract was 13%, for duplicate independent experiments it was 31%. 
 
Figure 9: Schematic of the filter- culture approach. Taken from 69. 
 
4.3.4.5 Anion-exchange liquid chromatography 
Negatively charged analytes are amenable to anion-exchange chromatogra-
phy (AEC), where they are usually eluted with increasing concentrations of 
sodium hydroxide and/or sodium acetate. However, the high salt concentra-
tions are detrimental to mass spectrometric analysis. To solve this problem, 
Dionex Inc. introduced a postcolumn self-regenerating suppressor. This 
device electrochemically exchanges cations for protons.70 AEC was used in 
several studies, mainly to investigate glycolytic intermediates, many of which 
were phosphorylated. AEC was coupled to a QQQ-MS in MRM mode with 
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negative ionization. LODs were in the range of 42-440 μM, with a linear range 
of about two orders of magnitude. Quantitative results were compared with an 
enzymatic assay and very good correlations were observed.70 Several studies 
have described the combination of rapid sampling from a bioreactor for S. 
cerevisae and the subsequent analysis of glycolytic intermediates by AEC.71-73 
While the method seems to provide reasonable resolution for negatively 
charged metabolites, it suffers from poor sensitivity (LODs in the middle to 
high μM range) and limited dynamic range due to incomplete removal of ions 
in the suppressor. 
4.3.5 Gas chromatography 
4.3.5.1 GC-MS 
Gas chromatography (GC) is still the method preferred for global metabolome 
studies.6-8 It is very well suited for the analysis of polar small molecules upon 
derivatization, which is commonly done by silylation, provided the derivatives 
are stable at the high temperatures used in GC. GC-MS was used to quantify 
metabolites in different microorganisms.74 Many different metabolite classes, 
such as alcohols, amines, fatty acids, organic acids, sugars and others, could 
be analyzed, with relative standard deviations mostly below 10%. LODs were 
40-500 pg on-column, corresponding to 0.1-0.7 mmol/g dry weight. The 
method was applied to the analysis of E. coli samples harvested at different 
growth phases. Another application was the use of GC-MS for the evaluation 
of sample preparation methods in yeast.75 Amino acids and organic acids 
were derivatized with methylchloroformate, sugars and related compounds as 
well as peptides were analyzed after oximation-silylation. The effect of 
quenching, extraction and water evaporation on metabolite recovery was 
assessed and the most suitable protocols were highlighted. 
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4.3.5.2 GC-TOF-MS 
The introduction of GC-TOF-MS hyphenation allows the use of GC, a robust 
separation technique, for the screening and identification of unknown metabo-
lites. In a proof-of-principle study, 77 metabolites found in C. reinhardtii under 
different conditions were relatively quantified.7 Principal component analysis 
(PCA) was performed on 177 metabolites, both known and unknown, which 
allowed the clear separation of the different experimental groups. Later on, 
GC-TOF-MS was used for the discrimination of invasive ovarian carcinomas 
and ovarian borderline tumors based on their different metabolic patterns.76 
PCA and supervised predictive models allowed the separation of 88% of the 
borderline tumors from the carcinomas. However, only nine borderline tumors 
were analyzed in the study as compared to 66 invasive carcinomas. 
4.3.5.3 GCxGC-TOF-MS 
Comprehensive two-dimensional gas chromatography (GCxGC) is a very 
powerful technique, based on the separation of gas phase analytes on two 
capillary columns with complementary interactions. A modulation device 
focuses the effluent from the first column in small segments, which are subse-
quently injected as narrow bands onto the second column, usually a short 
column suitable for high-speed separations.77, 78 The use of two orthogonal 
columns results in a multiplicative increase in peak capacity in the GCxGC 
system in comparison to 1D-separations on the respective columns. In addi-
tion, the focusing step during modulation produces very narrow peaks and, 
consequently, lower detection limits. 
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Figure 10: Schematic diagrams of various modulators used for GC×GC that trap solute 
coming from the primary dimension (D1) and pulse it to the second dimension (D2): (A) a 
heated tube encasing the capillary column; (B) the thermal sweeper system with a rotating 
slotted heater sweeping over the accumulation column to collect and pulse solute to the 
second column; (C) theLMCS that uses an oscillating cryotrap to trap the solute peak (position 
T), thus allowing it to heat up and remobilize by moving to the release position (position R); 
(D) a dual jet modulator using two jets to supply localized cryogenic cooling to the column; and 
(E) an example of the valve system that partially fills a loop and then switches the valve to 
flush the loop to the second column (the diagram shows the valve in the flush position). Taken 
from 78. 
Data analysis is still a major problem for 2D separations, because programs 
available to date were derived from software designed for 1D separations. The 
analysis of known components can usually be done with proprietary software 
from instrument vendors such as HyperChrom (Thermo) and ChromaTOF 
(LECO). Parallel factor analysis (PARAFAC) can be used for the deconvolu-
tion and quantification of overlapping peaks in higher order data.79 The newer 
PARAFAC2 algorithm is even able to handle less-than-ideal 2D data where for 
example run-to-run retention time shifting has occurred. However, one 
problem of this approach is the requirement for identical peak shapes for one 
particular analyte in all the analyzed runs. 
 31
GCxGC-TOF-MS was used for the analysis of the yeast metabolome upon 
cycling oxygen consumption.79, 80 Applying several data analysis tools 
including PARAFAC and PCA, 44 metabolites of known identity, such as 
methyl citrate, myo-inositol, G6P and cystathionine, as well as 41 unidentified 
compounds were found to exhibit an oscillatory behavior over time. 
Organic and amino acids of the central carbon metabolism were analyzed by 
GCxGC-TOF-MS in M. extorquens under two different growth conditions.81 
Quantification was only performed over one order of magnitude, by spiking 
target compounds into the samples. PARAFAC analysis was used to remove 
noise and overlapping peaks, and several changes in pool sizes were found 
that corresponded well with flux data. 
GC-TOF-MS and GCxGC-TOF-MS were compared for the metabolomic 
analysis of mouse spleen tissue.82 Seven times more abundant and high 
quality peaks were found with the two-dimensional analysis. However, the 
high-information content of the obtained chromatograms necessitated the use 
of sophisticated data analysis software. Some of these tools, such as direct 
chromatogram comparison, chromatogram subtraction and averaging routines 
as well as weighted chromatograms and Student’s t-test, were compared and 
contrasted.82 
4.3.6 Comparison of methods for the analysis of central carbon 
metabolites  
The single quadrupole mass analyzer has the advantage of being inexpensive 
and robust. Used in SIM mode, it yields good detection limits and linearity. 
However, only unit mass resolution can be achieved and no MS/MS experi-
ments can be performed. Triple quadrupole MS offers robustness and various 
MS/MS techniques. Using the instrument in MRM mode allows the specific 
and sensitive analysis of multiple analytes of interest. However, prior 
knowledge of the analytes is required for this scan type. Triple quadrupole MS 
is less sensitive in scan mode and gives only unit mass resolution, which leads 
to a high number of metabolite hits that cannot be discriminated. For 
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screening applications, a TOF-MS is more suitable. The new generation of 
TOF-MS has the advantage of yielding high mass accuracies (typically 3-5 
ppm) at high data acquisition rates over a wide dynamic range. But since 
background ions cannot be removed, detection limits are higher than on a TQ 
operated in MRM mode, which, however, carries the disadvantage that only a 
limited number of metabolites can be measured. This may be overcome in the 
future with the introduction of scheduled MRMs (Applied Biosystems). Also, 
the TOF is more sensitive to environmental changes, thus necessitating 
regular recalibration and tuning. 
CE-MS has the advantage of high peak capacities and resolution, while using 
only minute sample amounts. However, increasing injection amounts is diffi-
cult, therefore LODs are usually higher than those observed for LC-MS. 
Among LC-MS or LC-MS/MS methods, IP-LC-MS is well suited for polar ana-
lytes. Nevertheless, the IP reagent may cause ion suppression and fouling of 
the instrument. HILIC has the advantage of using solvents that are highly 
suitable for LC-MS analysis, yet retention times are often less reproducible 
compared to other LC methods. One advantage of HILIC over CE-MS is its 
ability to separate noncharged polar compounds such as sugars. While AEC 
provides reasonable resolution for negatively charged metabolites, it suffers 
from poor sensitivity, with LODs typically in the middle to high μM range, and a 
limited dynamic range. GC-MS, in comparison, is a very robust method and 
the excellent reproducibility of retention times and MS fragmentation patterns 
carries the advantage that analytes can be identified by mass spectral simi-
larity and retention index comparison with commercial and custom libraries of 
standards. However, polar analytes are only amenable to GC-MS analysis 
after derivatization and thermolabile compounds cannot be measured. A com-
parison of important approaches towards metabolome analysis is shown in 
Table 1. 
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Table 1: Comparison of selected approaches for the metabolic analysis of the central carbon metabolism 
Method Advantages Disadvantages LOD Ref. 
MALDI-TOF-MS • Well suited for screening • Simple sample preparation  
• Poor linear range 
• Poor quantification 
• Poor reproducibility 
15 nM – 1 μM 42-46 
CE-TOF-MS 
• No derivatization necessary 
• High peak capacities 
• Low sample consumption 
• High mass accuracy 
• Well-suited for screening 
• High LODs reg. concentrations 
• Sensitive to sample ion strength 
• No fragmentation 
0.2 – 2 μM 49, 83 
PGC-LC-IT-MS • High resolution of polar compounds • High resolution of isomers 
• Often complicated gradients needed 
• Limited linear range 0.1 – 1.5 μM 
56-59 
UPLC-MS 
• Increased efficiency 
• Higher peak capacities 
• Faster separations possible 
• High pressure 
• Specialized equipment required  
61-63 
IP-LC-MS/MS 
• Good resolution of polar compounds 
• Good linearity over a wide range 
• Very low detection limits 
• Very good reproducibility 
• Ion suppression 
• Fouling of the MS caused by IP 
reagent 
0.1 – 500 nM 11, 66, 67 
HILIC-MS 
• Good retention of polar compounds 
• Solvents well-suited for MS 
• Suited for uncharged compounds 
• Poor reproducibility of retention 
times 
• Poor reproducibility 
 3, 5, 69 
AEC-MS • Well-suited for charged analytes • Good resolution of sugar phosphates 
• Poor sensitivity 
• Limited dynamic range 42 – 440 μM 
70-73 
GC-MS 
• Very robust method 
• High reproducibilities 
• Suitable for a wide range of analytes 
• Identification of unknowns via libraries 
• Requires derivatization 
• Not suited for thermo labile 
compounds 
40-500 pg on 
column 
74, 75 
GCxGC-TOF-MS • Very high peak capacities • Improved S/N ratios 
• Compound identification difficult 
• Quantitative capabilities have yet to 
be assessed 
 77-82 
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4.3.7 Flux analysis 
The methods described above are mostly used for the analysis of the metabo-
lite composition of a given biological system. However, in order to investigate 
the overall behavior of a network, it is important to also gain information on in 
vivo reaction rates. Since it is not possible to measure these rates per se, 
metabolic flux analysis uses different methods for the indirect measurement of 
metabolic reaction rates.84 Different strategies have been applied to analyze 
and quantify intracellular fluxes and metabolic networks, analysis is usually 
performed by mass spectrometry (MS) or nuclear magnetic resonance (NMR) 
based methods.85  
The most common approach consists of feeding the cells a labeled substrate, 
usually 13C labeled glucose, and then analyzing the label distribution, either in 
proteinogenic amino acids or in metabolic intermediates. The analysis of 
labeled amino acids is commonly done by GC-MS. For instance, this approach 
was used to investigate different E. coli strains with mutations in the central 
carbon metabolism. It was demonstrated that the oxidative PPP was substan-
tially decreased under anaerobic conditions in a wild type strain and that upon 
a complete block of glycolysis the Entner-Doudoroff (ED) pathway contributed 
about 30% to glucose catabolism.86 In another study, flux analysis by GC-MS 
led to the observation of substantial flux rerouting from glycolysis towards PPP 
upon a block in the the direct transfer of a reducing equivalent from NADH to 
NADPH.12 Complex changes of carbon flux throughout the central metabolism 
were observed in S. cerevisiae after a shift from oxidative to fermentative 
growth.87  
The second approach to metabolic flux analysis is the direct measurement of 
labeling distributions in intermediates of the central carbon metabolism. The 
analysis of flux distribution between glycolysis and PPP was performed by 
GC-MS measurement of lactate and ribose labeling, derived from [1,2-
13C2]glucose.88, 89 Isotopomers of intracellular metabolites in E. coli were also 
measured by CE-TOF-MS.90 The results were compared with data from GC-
 35
MS analysis of proteinogenic amino acids. The correlation between the two 
methods was quite high, remaining differences were contributed to alterations 
in labeling distribution between precursors and amino acids as well as influ-
ences from flux modeling.90 
Several effects have to be taken into account when performing flux analysis by 
GC-MS. The sample has to be prepared by chemical derivatization, as 
described above, mainly by oximation and silylation.12, 86 However, silicon has 
a significant percentage of naturally occurring isotopes, namely 4.7% 29Si and 
3.09% 30Si. Also, strong isotope effects have been observed, which led to 
different retention times of differently labeled isotopomers in GC columns.91  
There are only few reports on the use of LC-MS based methods in the context 
of flux analysis. The advantage of these methods is that no derivatization is 
necessary, thus correcting for natural isotopes is easier. An IP-LC-MS/MS 
based method was used to study the effect of a short glucose pulse in E.coli 
applying ultra-fast sampling.92 Anion-exchange chromatography was used to 
evaluate mass isotopomer distributions of primary metabolites, which was 
subsequently fitted with a model to yield metabolic flux data.93 A method for 
flux analysis in fed batch cultures by measuring intracellular free amino acids 
was described.94 However, amino acids had to be derivatized prior to LC-
MS/MS in order to increase their ionization efficiency. 
4.3.8 Platform approaches 
The future of metabolomics is definitely its integration with genomics and 
proteomics in order to gain a complete picture on cellular processes. The first 
step in this regard will be to combine different analytical techniques for a com-
prehensive coverage of the metabolome. For example, UPLC-MS, HILIC-MS 
and GC-TOF-MS approaches were combined for the analysis of the urinary 
metabolome.95 Automated peak picking was performed with MZMine and 
XCMS, both freely available online. The extracted features were then used to 
discriminate samples from patients with renal cell carcinoma from healthy 
controls (n=6 each). For all three methods significant features were detected 
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that could discriminate the two groups, however no identification of these 
features was attempted.  
A more comprehensive approach employed six different methods for me-
tabolome analysis for microbial metabolomics.96 First, available metabolome 
information from three microorganisms (E. coli, B. subtilis and S. cerevisiae) 
was compiled in a list that comprised 905 different metabolites. The list was 
generated from the metabolite databases for these organisms after manual 
curation. Then, three GC-MS and three LC-MS methods were used to analyze 
399 compounds commercially available, 380 of which were ultimately 
amenable to analysis. When applied to exponentially growing E.coli cell 
extracts, 431 peaks were detected and 176 metabolites could be identified, 
including 61 that were not previously annotated in existing E. coli databases. 
The integration of multiple high-throughput measurements of alterations in 
mRNA, proteins, metabolites and fluxes was recently done by Ishii et al. 97 An 
E. coli wild type strain and 24 single-gene mutants were analyzed by six 
different methods. Gene expression was measured by DNA microarrays and 
qRT-PCR, protein expression by two-dimensional differential gel electro-
phoresis and LC-MS/MS, metabolite levels by CE-TOF-MS and fluxes by GC-
MS of 13C-label distributions in proteinogenic amino acids. The authors could 
demonstrate that the intracellular metabolic network in E. coli was stable 
towards various types of perturbations. 
4.4 Sample preparation 
Sample preparation is of high, but often neglected importance for the general 
validity of results obtained from a metabolomic experiment. The two most 
crucial steps in sample pretreatment are the rapid quenching of metabolism 
and the extraction of metabolites. Both steps may introduce systematic or 
random errors. For example, if the effect of a pulsed perturbation on the 
metabolism is investigated, fast sampling and quenching of the metabolism is 
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of utmost importance, since numerous metabolites have turnover times of less 
than one second.57  
However, the most common quenching method, which employs rapid transfer 
of the sample into a cold methanol:water mixture, leads to substantial metabo-
lite leakage from cells that do not possess a strong cell wall, such as different 
bacterial strains including E. coli or human cell lines.98-100 Alternative methods 
for quenching have been described, for example the fast sampling into a 
syringe containing pre-cooled stainless steel beads.100 Very rapid sampling 
with intervals of less than 5 s and immediate quenching on a subsecond time 
scale (<200 ms) was described for S. cerevisiae.73 Another strategy is the 
combined measurement of intra- and extracellular metabolites, for example 
after rapid heating of the sample to 95ºC, where intracellular metabolites are 
released quantitatively to the surrounding medium.101 However, for this 
approach extracellular metabolite concentrations have to be substracted, 
which increases the influence of measurement errors. A method for steady-
state measurements, where rapid changes are not supposed to occur, is the 
fast filtration of the broth, to separate cells from the media. This approach was 
found to substantially reduce leakage, especially for gram-positive strains.98, 99 
Secondly, the metabolites have to be released from the cells and this process 
should be complete or at least reproducible. A number of different extraction 
methods were proposed,102 but only a few studies have compared different 
methods to date.75, 103, 104 It is to be expected, that different methods will yield 
optimal results for different organisms or metabolite classes. This was 
comprehensively demonstrated in a recent evaluation of different solvent 
mixtures for the extraction of metabolites from E. coli.105 It was found that 80% 
methanol/water is well suited for many metabolites. However, a number of 
phosphorylated compounds, especially nucleotide triphosphates, are severely 
reduced under these conditions. For these compounds, mixtures of acidic 
acetonitrile/water (80:20) or acetonitrile/methanol/water (40:40:20) gave 
superior yields due to reduced decomposition. Optimization of extraction 
protocols for mammalian cells was performed by fractional factorial design, 
 38
based on the evaluation of different conditions on four response variables.106 
Methanol/chloroform and boiling methanol yielded overall the best results. 
4.5 Data analysis 
4.5.1 Handling of complex metabolomic datasets 
Typical metabolomic experiments can generate large amounts of data. 
Handling such complex datasets has a huge impact on the quality of metabo-
lite identification and quantification, and thus on the ultimate biological inter-
pretation of the results. This has led to an increased development of methods 
and software tools for metabolomics in the recent years. The common data 
processing routine consists of several stages, including filtering, feature 
detection, alignment and normalization.107 However, in order to process the 
raw data derived from different proprietary mass spectrometer softwares, it 
has to be converted into a common data format, usually netCDF or mzXML. 
Several programs are available for feature detection 107, both commercial, e.g. 
MarkerLynx, MassHunter, Metabolic Profiler, metAlign, and freely available, 
e.g. MathDAMP, MET-IDEA, MZmine, XCMS. MZmine 108, 109 has the advan-
tage that it can handle both netCDF and mzXML data and align the extracted 
features from multiple samples. While MZmine (Figure 11) is well suited for 
CE-MS and LC-MS analysis, it does not perform spectral reconstruction. This 
complicates data-sets derived by EI-GC-MS, where considerable fragment 
generation occurs. The program MET-IDEA 110 is able to use data extracted 
from AMDIS, a software used for the deconvolution of GC-MS data. MET-
IDEA eliminates noise, corrects for retention time shifts and automatically 
detects and quantifies all potential metabolites.  
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Figure 11: MZmine graphical user interface: (A) List of imported raw data files. (B) Total ion 
chromatogram (TIC) for selected file. (C) Mass spectrum for selected retention time for the 
same file. (D) Peak list for the same file, with listed m/z values, retention times, and intensities. 
(E) 2D map of the same file, with retention time on x-axis and m/z on y-axis. (F) Zoomed-in 
spectra for a different file. (G) Peak alignment matrix for all files listed. (H) Available alignment 
results, e.g. for different normalizations. Taken from 109. 
The extracted features from CE- or LC-TOF-MS data are usually characterized 
by their exact mass, their retention / migration time and potentially their 
molecular formula. Especially the mass information can now be used to query 
a database for potential metabolite identification. A comprehensive collection 
of available databases can be found in 111, 112. In order to confirm the obtained 
hits, ideally a commercial standard can be measured. If this is not possible, 
the structure of the putative identification can be cross-checked with closely 
eluting compounds to check for plausibility. If available, the molecular formula 
is also a valuable confirmation. 
In GC-MS is the identification of unknown metabolites poses additional 
problems due to the fragmentation occurring under electron impact ionization. 
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Usually identification is performed by database search, commonly the AMDIS 
database, however if a compound is not included in the reference database, it 
can not be identified and tracked with this approach. Recently, a program 
termed SpectConnect was introduced, which compares every spectrum in 
each sample to the spectra in every other sample.113 By this it can determine 
which components are conserved across replica samples and also detect 
differences between different conditions. 
4.5.2 Quantification 
Quantification is an issue of high importance in metabolomic studies. 
Knowledge on absolute quantities of metabolites is important for the modeling 
of cellular networks and to evaluate responses to external stimuli. Initially, 
quantitation was often performed in a relative fashion or by using a single 
internal standard compound as reference. Recently, the use of several internal 
standard compounds, often stable isotopes of key analytes, was shown to 
yield better reproducibilites, especially if standards are introduced at different 
stages during sample preparation and measurement.74, 83, 114 An elegant 
method to account for many different potential interferences, such as partial 
degradation of metabolites, non-linearity, instrument drift or matrix effects, was 
introduced recently.115 S. cerevisiae was grown on [U-13C]glucose, the ex-
tracted metabolites were subsequently used as internal standards for metabo-
lite quantification. The method was termed "Mass Isotopomer Ratio Analysis 
of U-13C Labeled Extracts" (MIRACLE).116 The same mixture was used later 
for the analysis of metabolites of Penicillium chrysogenum. Intracellular me-
tabolites were quantified with relative standard deviations (RSDs) of ≤5%.117 
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5 Experimental section – Materials and 
Instrumentation 
5.1 Chemicals 
All metabolite standards, ammonium acetate, LC-MS grade water, 2-propanol 
(LC-MS grade), 1,2-bis(3-aminopropylamino)ethane, epichlorohydrine, LB and 
M9 broth, methoxylamine hydrochloride, amino acid standard solution, 
pyridine, LC-MS grade acetic acid, tributylamine and [U-13C, U-15N]AMP were 
from Sigma (Sigma-Aldrich, Taufkirchen, Germany). Methanol (LC-MS) was 
from Fisher (Fisher Scientific GmbH, Ulm, Germany). All solvents were HPLC-
MS grade. [U-13C]lactate, [U-2H]succinate and [2,2,4,4,4-2H5]glutamic acid, [U-
13C]glucose, [2,3,3,3-2H4]lactate , [U-13C]fumarate and the [U-13C, U-15N] cell 
free amino acids mixture were from Euriso-top (Saint-Aubin Cedex, France). 
DL-[2,3,3-2H3]malic acid and [U-13C]pyruvate (MSTFA) were purchased from 
C/D/N Isotopes Inc. (Quebec, Canada). N-methyl-N-trifluoroacetamide was 
from Macherey-Nagel (Dueren, Germany). [U-13C]glucose-1-phosphate and 
[1,2-13C2]glucose were from Omicron Biochemicals Inc. (South Bend, IN, 
USA). The EZ:faast kit for GC-MS was obtained from Phenomenex Inc., 
Torrence, CA, USA. 
5.2 Instrumentation 
Capillary electrophoresis was performed on an HP3D-CE system (Agilent 
Technologies, Palo Alto, CA, USA). For CE-TOF-MS the CE capillary was 
coupled to a MicrOTOF Focus (Bruker Daltonics, Bremen, Germany) via a 
coaxial CE-ESI sprayer. Sheath liquid was delivered by an 1100 series 
isocratic pump (Agilent Technologies).  
Shake flasks for cultivation of E. coli cells were incubated in an Innova 4430 
Incubator Shaker (New Brunswick Scientific GmbH, Nuertingen, Germany).  
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Optical density measurements were performed on an Ultrospec 3100 pro 
UV/VIS Spectrophotometer (Amersham Biosciences, Buckinghamshire, UK). 
Solvent evaporation during sample preparation was performed on a Combi 
Dancer Infra-Red Vortex-Evaporator (Hettich AG, Baech, Switzerland). 
A pH-electrode Lab 850 (SCHOTT Instruments GmbH, Mainz, Germany) was 
used for the adjustment of pH values of buffers and solvents. 
For the sterilization of all the materials used for the cultivation and preparation 
of bacterial and cell culture samples a steam sterilizer Varioklav (Thermo 
Fisher Scientific Inc, Waltham, MA, USA) was used. 
GC-MS for most metabolites was performed on an Agilent Technologies 
Model 6890 GC equipped with a 5975 Inert XL Mass Selective Detector (MSD) 
and a 7683B Auto Liquid Injector. GC-MS analysis of amino acids was per-
formed on an Agilent Technologies Model 6890 GC equipped with an 5975 
Inert XL MSD, a PTV injector (Gerstel, Muehlheim, Germany) and a MPS-2 
sample robot (Gerstel).  
An Agilent 1200 SL HPLC system (Agilent Technologies, Waldbronn, 
Germany) was used for liquid chromatography. The HPLC system was directly 
coupled to a 4000 QTRAP mass spectrometer (ABI/MDS Sciex, Concord, 
Canada). Direct infusion was performed using a model 11 PLUS syringe pump 
(Harvard Apparatus, Holliston, USA). 
5.3 Software 
Analysis of the data generated on the MicrOTOF instrument was performed 
using DataAnalysis 3.4 and QuantAnalysis 1.8 (Bruker Daltonics, Bremen, 
Germany). Peak picking and alignment were performed with MZMine, version 
0.60. Analysis of data generated on the 4000 QTRAP instrument was 
performed with Analyst 1.4.2. 
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6 CE-TOF MS method development 
6.1 Introduction 
As described in chapter 2, different methods are used for metabolome analy-
sis. The feasibility of CE-MS for metabolomics and its quantitative capabilities 
have been demonstrated in several studies.10, 25, 50, 118-122 Recently, the 
coupling of CE to a TOF-MS was shown to yield much more information in a 
single run, than could be achieved on a single quadrupole instrument.49  
Our goal was the development of a CE-TOF-MS method for quantitative 
metabolic profiling of negatively charged metabolites. To this end, we used 
capillaries coated with a cationic polymer to reverse the EOF. We optimized 
the coating procedure as well as the background electrolyte and the sheath 
liquid. A method to correct for shifts in migration time was introduced. Finally 
the quantitative capabilities of the method for 20 selected metabolites involved 
in the central carbon metabolism were established and several quality control 
steps were introduced to ensure a reliable measurement over an extended 
period of time. A shortened version of this chapter was published as part of 83. 
6.2 Methods 
6.2.1 Experimental details of the optimized CE-TOF-MS method 
Capillary electrophoresis was performed on an HP3D-CE system (Agilent 
Technologies, Palo Alto, CA, USA). Prior to use, fused-silica capillaries 
(Polymicro Technologies, LLC, Phoenix, AZ, USA; 100 cm x 50 μm ID) were 
coated with PolyE-323 for 20 min as described in 123 to reverse the EOF. After 
coating, the capillaries were equilibrated for 20 min with background electro-
lyte (BGE), containing 50 mM ammonium acetate, pH 8.7, in 5% (v/v) 
methanol in water. Sample was injected by applying a pressure of 50 mbar for 
30 s (25.8 nL, 1.31% of capillary volume). Metabolites were separated by 
applying a voltage of -30 kV for 21 min. The capillary was washed between 
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runs with 10 mM sodium hydroxide and water, and then re-equilibrated with 
BGE for 7 min. Total analysis time amounted to ~30 min. 
The capillary was coupled directly to a MicrOTOF Focus (Bruker Daltonics, 
Bremen, Germany). A 50% (v/v) isopropanol:water solution containing 20 mM 
ammonium hydroxide served as sheath liquid in the coaxial CE-ESI sprayer, 
delivered by an 1100 series isocratic pump (Agilent Technologies) at 4 μL/min. 
Ionization was performed in negative mode at 4500 V, assisted by a nebulizer 
pressure of 0.4 bar and a drying gas flow of 6 L/min at 200°C. The TOF 
detector was set to scan a mass range of 40-800 m/z at 3 scans/s. Resolution 
of the TOF-MS was typically ~10,000 at m/z 100 and ~15,000 at m/z 300. 
Mass recalibration was performed during post-processing by using sodium 
acetate clusters formed during the wash step with sodium hydroxide, leading 
to a reproducible mass accuracy of ~3-5 ppm. 
Absolute quantitation of 20 different metabolites, including 2KG, F6P, G1P, 
G6P, FBP, AMP, ADP, NAD, glutamate, aspartate, glycerol-1P, glycerol-2P, 
fumarate, oxaloacetate, lactate, pyruvate, malate, succinate, citrate, and 3PG, 
was accomplished with a dilution series of an equimolar (100 mM) aqueous 
stock solution of all standards (= standard mix), to which 100 μM each of the 
extraction and internal standard compounds [U-13C]lactate, [U-2H]succinate, 
glutamic acid-d5, malic acid-d3 and PIPES had been added. Prior to analysis 
of biological samples, 11 calibration points were generated over a 
concentration range of 1-1000 μM. Spectral peak integration was done with 
QuantAnalysis (Bruker Daltonics) following normalization of the peak areas of 
the standards to the area of the closest migrating internal standard. 
Concentrations were then inferred from the calibration curves. Stability of 
measurement was checked by periodical injection of a quality control sample 
between biological samples. 
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6.3 Results and Discussion 
6.3.1 Choice of capillary coating 
At pH-values above 5, the negatively charged silanol groups on the inner sur-
face of a bare fused silica capillary generate an EOF towards the cathode 
during electrophoresis, which is unfavorable for the analysis of anions. This 
may be remedied by coating the inner capillary surface with a cationic layer, 
resulting in the reversal of the EOF. Initially, capillaries commercially coated 
with hexadimethrine bromide 10 were used. However, in our hands, they 
yielded poor reproducibility of migration times and quantitative measurements, 
respectively (data not shown). Therefore, we switched to PolyE-323, a cationic 
polyamine.123 Preparation of the PolyE-323 coating solution proved simple and 
inexpensive. Coating was performed off-line with a PHD 2000 syringe pump 
from Harvard Apparatus (Holliston, MA, USA) to prevent fouling of the ion 
source with the cationic polymer. The coating remains stable for at least 60 
runs. A drop in CE current of >20% indicates that the capillary has to be re-
coated or a new capillary has to be prepared. 
6.3.2 Optimization of the background electrolyte 
Ammonium acetate was used as BGE, because its ions are volatile and do not 
interfere with mass spectrometry. Of the different concentrations of ammonium 
acetate evaluated (25 mM, 40 mM, 50 mM, and 60 mM), 50 mM gave baseline 
resolution for all compounds except F6P and G6P (Rs~1.3), see Figure 12 for 
a chromatogram under optimized conditions. In addition, a reasonably fast 
analysis time of ~30 min per sample, including pre- and post-conditioning, was 
obtained. Using buffers with lower ionic strength significantly increased 
analysis time, while an ammonium acetate concentration of 60 mM failed to 
resolve F6P, G6P and G1P. 
Next, different pH values were tested (8.5-9.1). Optimization parameters were 
resolution of the hexose-phosphates, relative migration times (MT) of the 
metabolites, peak shape and coating stability. The coating was stable under 
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all pH conditions, but peaks substantially broadened at pH values >9. A pH of 
8.7 was found to yield overall the best results. 
We also tested the addition of different organic modifiers to the BGE.118 A 
methanol concentration of 5% (v/v), to reduce unwanted analyte-wall interac-
tions, in 50 mM aqueous ammonium acetate, pH 8.7, gave the best results for 
the resolution of the hexose-phosphates, while peaks broadened significantly 
at methanol concentrations >10%. The addition of acetonitrile or isopropanol 
to the BGE yielded electrophoretic separations inferior to methanol. 
6.3.3 Sheath liquid optimization 
The use of isopropanol (50% v/v in water) as sheath liquid proved superior to 
methanol in ensuring spray stability. As the volatile ionic constituent in the 
sheath liquid we chose ammonium hydroxide, because it increases the pH of 
the solvent and, thus, increases ionization efficiency in negative mode. We 
tested different concentrations of ammonium hydroxide (5 mM, 20 mM, 50 mM 
and 280 mM). Performance was best at 20 mM. At 5 mM, the ionization 
efficiency of certain analytes (e.g., aspartate, citrate, fumarate) deteriorated. 
Ionization did not increase at concentrations >20 mM, but the mechanical sta-
bility of the fused silica capillary was affected. Especially at the highest con-
centration, the capillary became brittle and the polyimide coating detached 
from the outer capillary surface over the course of a day. Therefore, 20 mM 
ammonium hydroxide in water-isopropanol (50:50, v/v) was used for all CE-
MS analyses as the sheath liquid, which was delivered by an isocratic pump at 
a flow-rate of 4 μL/min. The extracted ion chromatograms (EIC) for selected 
metabolites under optimized method parameters are shown in Figure 12. 
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Figure 12: Extracted ion chromatograms of A) a mixture of standards (31.25 μM each ) and 
B) an E.coli wild type sample (grown in M9 medium). Lac, lactate; Succ, succinate; Glyc-P, 
glycerol-phosphate; Asp, aspartate; 2KG, 2-ketoglutarate; Glut, glutamate; Pyr, pyruvate; Mal, 
malate; Fum, fumarate; Cit, citrate; Hex-P, hexose-phosphate. 
A 
B 
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6.3.4 Migration time shift 
A common problem in CE is MT shift between injections. This effect is de-
pendent on the ionic strength of a sample, which leads to different stacking 
conditions and, thus, to different effective field strengths in the capillary. In 
addition, the complex matrices of biological samples often contain compo-
nents that interact with the inner capillary surface, leading to alterations in 
EOF.124, 125 To minimize the latter, capillaries were flushed sequentially with 
BGE (30 s), 10 mM NaOH (1 min) and water (30 s), followed by equilibration 
with BGE for 7 min. Nevertheless, MT was still not sufficiently constant to 
serve as a reliable criterion for metabolite identification. Therefore, we imple-
mented an algorithm that corrects for MT shifts as proposed by Reijenga et al. 
49, 124 Whereas the latter used two arbitrary sample peaks, we chose to use 
internal standards, thus eliminating the need for prior knowledge of analyte 
composition. To this end, three internal standards, namely glutamic acid-d5, 
malic acid-d3 and PIPES, were added to every sample at a final concentration 
of 100 μM. Standard runs in freshly coated capillaries were used to determine 
migration times under reference conditions. 
 
Figure 13: Effect of correcting for spray fluctuations and MT shift. Glutamic acid-d5, malic 
acid-d3 and PIPES are used as internal standards, n=55; left: not corrected, right: corrected. 
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We tested the correction method by measuring a total of 45 injections of 
metabolite standard and 5 injections each of two different biological samples 
in one batch. Relative standard deviations for peak areas were ~10-15%, for 
migration times ~10%. They were reduced to 5-7% for peak area and 0.07-
0.13% for migration time after applying the corrections described above 
(Figure 13). This facilitates subsequent spectral alignment and, thus, 
identification of analytes.  
6.3.5 Quantitative metabolite analysis and quality control  
In order to achieve absolute quantitation of selected metabolites, calibration 
curves were generated. Calibration curve parameters as well as LOD and 
limits of quantitation (LLOQ, ULOQ) are presented in Table 2.  
Table 2: Calibration curve parameters for selected metabolites 
Metabolite RSQa) LODb) (μM) LLOQ (μM) ULOQ (μM) 
Lactate 0.9997 1 2 5000 
Pyruvate 0.9985 1 4 5000 
Oxaloacetate 0.9987 5 30 5000 
Citrate 0.9985 1 4 5000 
2KG 0.9986 0.5 1 2500 
Succinate 0.9975 0.5 1 2500 
Fumarate 0.9999 0.5 2 2500 
Malate 0.9963 0.25 1 5000 
Aspartate 0.9988 0.5 1 2500 
Glutamate 0.9998 0.5 1 5000 
G1P 0.9983 0.5 1 500 
G6P 0.9997 1 2 500 
F6P 0.9975 1 2 500 
FBP 0.9992 2 4 2000 
3PG 0.9962 2 4 2000 
Glycerol-1P 0.9966 1 2 2500 
Glycerol-2P 0.9988 1 2 2500 
AMP 0.9997 0.5 1 2500 
ADP 0.9999 2 4 2500 
NAD 0.9993 0.5 2 2500 
a) Square of the correlation coefficient r of the regression analysis 
b) Defined as a S/N ≥ 3 
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The LOD was defined as the concentration, at which a compound could be 
detected with a signal-to-noise (S/N) of ≥3. The LLOQ and ULOQ were de-
fined according to the FDA Guide for Bioanalytical Method Validation 126 as 
the lowest and highest points of the calibration curve, respectively, at which a 
compound could be measured with an accuracy between 80-120%. 
A number of quality control (QC) measures were introduced to ensure reliable 
and accurate quantitation of the metabolites of interest. Alterations of metabo-
lite levels during sample preparation were accounted for by adding 100 μM 
each of [U-13C3]lactic acid, [U-13C6]glucose, norvaline, succinic acid-d4 and 
cinnamic acid-d7 in methanol to every sample immediately before extraction. 
The extracts were dried by evaporation and reconstituted in MilliQ-water con-
taining 100 μM each of glutamic acid-d5, malic acid-d3 and PIPES. These 
internal standards were used to correct for shifts in migration time and altera-
tions in electrospray efficiency (as described above, see Figure 13). Samples 
within a batch were run in a random order. Prior to each batch, 11 calibration 
standards of different concentrations were analyzed to check for calibration 
curve stability. After every 8-10 biological samples, several QC samples were 
analyzed, consisting of 3 calibration standards (low, medium and high 
concentration), one biological replicate and a blank sample containing only 
internal standards. The QC samples and the samples associated with them 
were accepted only if at least 67% of the QC samples were within ±15% of 
their nominal value.126 The intra-day analytical variability of metabolite 
standards was 0.7 – 12.5%, while the inter-day variability ranged from 4.1% to 
12.3% (Table 3). 
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Table 3: Reproducibility of CE-TOF-MS and extraction of selected metabolites, and biological 
variability of four replicates each for two E. coli strains. 
Metabolite Variance, Std (%) Variance, E. coli samples (%) 
  
Intraa)- / Interdayb) 
n=4 / n=8 
Analyticalc)
n=4 
Extractiond)
n=3 
Biologicale) 
P-U, n=4 
Biologicale)
wt, n=4 
Lactate 0.7 / 4.5 12.4 16.5 23.9 19.5 
Pyruvate 6.7 / 9.1 5.4 7.9 24.8 19.1 
Citrate 10.4 / 11.4 9.6 11.3 4.5 14.0 
2KG 10.6 / 8.4_ 9.2 13.7 10.6 17.1 
Succinate 6.2 / 6.0 5.1 9.1 11.5 13.0 
Fumarate 11.4 / 10.7 4.1 10.6 19.8 27.6 
Malate 3.6 / 4.9 8.3 9.9 14.8 5.0 
Aspartate 8.5 / 8.6 7.8 9.0 7.3 14.3 
Glutamate 4.8 / 5.3 6.1 11.7 3.4 9.7 
G1P 2.7 / 8.9 10.6 14.7 13.0 9.7 
G6P 6.0 / 4.1 22.7 22.6 15.7 31.3 
F6P 5.1 / 10.4 19.3 15.4 18.2 31.3 
FBP 9.9 / 11.2 12.3 13.6 24.2 22.9 
3PG 2.9 / 8.5 12 11.7 18.0 22.3 
Gycerol-1P 12.5 / 8.9_ 10.8 15.6 17.4 14.9 
AMP 4.8 / 7.0 3.9 11.9 30.7 5.1 
ADP 8.9 / 9.8 12.6 17.0 29.2 18.1 
NAD 11.2 / 12.3 3.7 11.4 10.4 24.8 
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7 Optimization of sampling and method validation for 
Escherichia coli 
7.1 Introduction 
Sample preparation is of high importance for the validity of results obtained 
from a metabolomic experiment. The two most important points in this regard 
are the rapid quenching of metabolic conversions after sampling and the 
sample work-up aimed at making all the metabolites amenable to analysis. 
Both steps have a high potential of introducing systematic or random errors if 
they are not sufficiently investigated and standardized and they have to be 
adapted to the specific biological problem at hand. Examples of different 
approaches for quenching and extractions were discussed in chapter 4.4. 
Considering all these factors we decided to use fast filtration for sample har-
vesting. We evaluated the filtration process with regard to different filter 
materials, as well as several extraction methods. We found significant 
differences for different sample preparation methods. In addition, we per-
formed a matrix spike experiment to establish the effect of the biological matrix 
on the absolute quantification of a selected set of metabolites. The results 
presented in this chapter were published as part of 83. 
7.2 Material and Methods 
7.2.1 Bacterial strains and growth conditions 
The E. coli wild type strain MG1655 and the mutant UdhA-PntAB (MG1655 
ΔudhA ΔpntAB) were cultured at 37ºC in 250 mL shake flasks containing 30 
mL of Luria-Bertani (LB) medium. After inoculation with a preculture in the 
same medium to an OD of 0.1, cells were harvested in stationary phase. Cell 
dry weight (cdw) was determined by vacuum filtration of 10 ml medium 
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containing cells at different optical densities. The filters were dried at 120ºC 
and weighed empty and with dried cells. 
7.2.2 Experimental details for cell harvesting and metabolite 
extraction 
2-10 mL of cell suspension (volume depending on OD) and pure medium (for 
method blanks and filter material evaluation), respectively, were filtrated by 
vacuum filtration using polyethersulfonate (PESU) filters resp. cellulose 
acetate, cellulose nitrate or regenerated cellulose for comparison of filter 
materials (0.45-μm pore size, 25 mm, Sartorius AG, Goettingen, Germany). 
The filters were then washed with an identical volume of NaCl solution (0.9%, 
room temperature), before they were submersed in 3 mL of 
quenching/extraction solution in a 50 mL Falcon tube (Fisher Scientific, 
Pittsburgh, PA, USA). The extraction solution consisted of 80% (v/v) methanol 
in water at -20ºC, containing the extraction standards [U-13C]lactate, [U-
2H]succinate, [U-13C]glucose, cinnamic acid-d7, and norvaline. The tube was 
vortexed for 45 s, the filter was removed and checked visually for complete 
dissolution of cells. 
The Falcon tube was transferred to liquid nitrogen for 3 min, thawed in an ice 
bath for 10 min, and briefly vortexed. This freeze-thaw cycle was repeated 
three times for complete cell disruption. The sample was centrifuged at 4ºC 
and 4.500 rpm for 8 min. The supernatant was transferred to a new tube. The 
pellet was re-extracted twice with 0.5 mL of 80% (v/v) methanol at -20ºC. The 
combined extracts were split into two aliquots, one for CE-TOF-MS and GC-
(AA)-MS analysis, the other for GC-MS analysis. The samples were dried for 4 
h in a vacuum evaporator (CombiDancer, Hettich AG, Bäch, Switzerland) and 
stored at -80ºC. For CE-MS analysis, the dried samples were dissolved in 100 
μL of internal standard solution containing 100 µM each of glutamic acid-d5, 
malic acid-d3, and PIPES. 
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7.2.3 CE-TOF-MS 
See Capter 6.2.1, optimized method parameters 
7.3 Results and Discussion 
7.3.1 Optimization of cell harvesting and metabolite extraction 
The rapid quenching of the cellular metabolism is critical in capturing the im-
mediate metabolic state and not an artificial distribution of metabolites 
generated by the sample handling process. The method commonly used is 
quenching in cold methanol. However, several studies found this procedure to 
cause a substantial leakage of metabolites, especially from prokaryotic cells 
such as E. coli.98, 99, 104 Instead we chose to harvest cells by filtration, which 
can be performed faster than centrifugation.99, 104 It takes about 1 min to filtrate 
and wash the sample. The filters were then immediately plunged into the cold 
extraction solution. This method might not be suitable for sampling continuous 
cultures or for evaluating pulse experiments, as some metabolites have turn-
over times of about 1 s. However, initially we were only interested in the meta-
bolic profiles of batch cultures in stationary phase, which we expected to 
contain a high number of different metabolites. 
Care has to be taken with regard to the filter material used for separating cells 
from medium. We tested four different filter types (cellulose acetate - CA, 
cellulose nitrate - CN, polyethersulfone - PESU and regenerated cellulose - 
RC) by filtering pure medium, followed by a wash with 0.9% NaCl solution and 
extraction with 80% methanol as described below. Lactate, glutamate, aspar-
tate, malate, succinate, glycerol-2P, and glycerol-1P were quantitatively 
determined in the extracts (Figure 14). We found that CN adsorbed most 
metabolites to a high extent, while the other three materials showed only 
minimal absorption. The lowest adsorption was seen for PESU, which was 
then chosen for further experiments. 
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Figure 14: Unspecific adsorption of metabolites to different filter materials. Ten mL of fresh LB 
medium (without cells) was filtered in triplicate through 4 different filter materials. The filters 
were washed with 0.9% NaCl, before extraction and analysis as described under 7.2.2. 
A number of methods have been reported for the extraction of metabolites 
from biological matrices. To date, however, only a few studies have compared 
directly the different extraction methods.75, 104 We adapted the cold methanol 
protocol by Maharjan et al. 104 that reportedly gave the best results for E.coli. 
We tested in triplicate 50%, 80% and 100% methanol for extraction efficiency 
of metabolites from E. coli (Figure 15). The extraction yield of NAD was signifi-
cantly higher in 80% than in 50% methanol. For carboxylic acids other than 
pyruvate, which could not be extracted in 100% methanol, no significant 
differences in extraction yield were observed between the three methanol 
concentrations tested. Contrary to findings in yeast 75, the use of 100% metha-
nol resulted in lower extraction yields of glutamate and aspartate. Finally, in 
concordance with Kimball and Rabinowitz 103, we found 80% methanol to work 
best for the extraction of phosphorylated metabolites, which was chosen for all 
subsequent experiments. 
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Figure 15: Effect of methanol:water ratio on extraction efficiency from E.coli cells. Cells were 
extracted in triplicates with different ratios of methanol:water (-20C) and analyzed with CE-MS. 
7.3.2 Quantification in biological matrices 
The validity of using calibration curves generated with aqueous metabolite 
standards for the quantitation of metabolites in biological samples was 
demonstrated by a matrix spike experiment. Briefly, metabolite standards at 
three different concentrations (15, 125 and 1000 μM) were added to the cold 
methanol extraction solution used for the extraction of E. coli cells. Each ex-
periment was performed in triplicate. Linear regression analysis was 
performed and the calculated slopes were compared to those obtained with 
standards in pure water. The correlation between the slopes for the individual 
analytes is shown in Figure 16. A slope of 0.94 and a correlation coefficient 
(RSQ) of 0.97 proved that for most metabolites no significant matrix effects 
had occurred. Only ADP and to a lesser degree PG and F6P/G6P were 
slightly over- or underestimated by using the aqueous standard curves. 
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Figure 16: Comparison of the slopes of calibration curves generated by standards either pre-
pared in water (y-axis) or in biological matrix (x-axis). E.coli cells were filtered and extracted in 
80% cold methanol containing increasing amounts of the 20 metabolite standard mix (0 μM, 
15 μM, 125 μM, 1000 μM). 
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8 Metabolome analysis of E. coli 
8.1 Introduction 
The metabolome of a microbe, while by far not as complex as that of a plant, 
still contains at least several hundred metabolites. For example the generation 
of in silico metabolomes, as described in chapter 4.3.8, of different 
microorganism species yielded 694 (E. coli), 537 (B. subtilis) and 458 (S. 
cerevisiae) different metabolites 96, i.e. low-molecular weight organic com-
pounds with molecular weights of less than 1000 Da. For many of these me-
tabolites, standards are not available commercially. It is therefore of great 
importance to develop methods that can screen for additional metabolites and 
provide high-confidence data leading to their identification. 
In the previous two chapters, the development of a method for the robust 
quantification of negatively charged metabolites was described. To further 
evaluate the capabilities of the CE-TOF-MS method it was used to elucidate 
metabolic changes in the Escherichia coli deletion mutant UdhA-PntAB that 
lacks nicotinamide nucleotide transhydrogenase function 12, under both 
stationary and exponential growth conditions. The reproducibility of metabolite 
extraction and CE-TOF-MS analysis as well as the biological variance were 
evaluated.  
In order to screen for additional metabolites, we adapted a freely available 
software tool, MZMine, for the specific challenges of CE-MS. We also 
established parameters to ensure the identification of potential metabolites 
with high probabilities. Finally, concomitant analyses with two different gas 
chromatography-mass spectrometry (GC-MS) methods allowed not only 
cross-validation of the quantitative results obtained by the various methods, 
but also led to a more comprehensive coverage of the E. coli metabolome. 
The results in this chapter, together with the findings from the previous two 
sections, were published in 83. 
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8.2 Material and Methods 
8.2.1 Bacterial strains, growth conditions and sample extraction 
The E. coli wild type strain MG1655 and the mutant UdhA-PntAB (MG1655 
ΔudhA ΔpntAB) were cultured at 37ºC in 250 mL shake flasks containing 30 
mL of Luria-Bertani (LB) or M9 minimal medium (0.1% NH4Cl, 0.6% Na2HPO4, 
0.3% KH2PO4, 0.05% NaCl) supplemented with 3 g/L glucose. After 
inoculation with a preculture in the same medium to an OD of 0.1, cells were 
harvested during strictly exponential growth or in stationary phase.  
All other conditions were the same as described in chapter 7.2. 
8.2.2 CE-TOF-MS 
See chapter 6.2.1, optimized method parameters 
8.2.3 Gas chromatography-mass spectrometry 
An Agilent Technologies Model 6890 GC equipped with a 5975 Inert XL Mass 
Selective Detector (MSD) and an 7683B Auto Liquid Injector was used for the 
separation of trimethylsilylated metabolites on a RXI-5MS column (30 m x 0.25 
mm ID x 0.25 µm film thickness, Restek, Bad Homburg, Germany). The initial 
oven temperature was set at 50°C, ramped at 8°C/min to 300°C, and held for 
10 min. Helium was used as carrier gas at a flow-rate of 0.6 mL/min. The 
transfer line to the mass spectrometer was kept at 310°C. The mass 
spectrometer was operated in full scan mode from 50 - 600 m/z with a scan 
time of 0.5 s. Sample volumes of 1 µL were injected in splitless mode at 
280°C. 
For derivatization 50 µL of 10 mg/mL methoxylamine hydrochloride in pyridine 
were added and incubated at 60°C for 60 min, followed by 50 µL MSTFA for 
60 min at 60°C. 
Calibration was performed using the standard solutions described above. 
Hundred µL of the different calibration levels were transferred into a glass vial 
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with glass insert and 10 µL of the surrogate solution containing [U-13C]lactate, 
[U-2H]succinate, [U-13C]glucose, cinnamic acid-d7 and norvaline (1mM each) 
was added. The standards were dried using a vacuum evaporator and 
derivatized as described above. 
8.2.4 GC-MS of amino acids 
An Agilent Technologies Model 6890 GC equipped with an 5975 Inert XL 
MSD, a PTV injector (Gerstel, Muehlheim, Germany) and a MPS-2 sample 
robot (Gerstel) was employed for amino acid analysis using a modified proto-
col from the Phenomenex EZ: faast kit. In contrast to the original protocol, the 
cation-exchange clean-up step was omitted. Amino acids were derivatized di-
rectly in the aqueous sample extract and extracted by isooctane. An aliquot of 
the organic extract (2.5 µL, 1:15 split) was injected into the GC-MS. Stable 
isotopes of amino acids were used as internal standards.  
The derivatives were separated on a ZB-AAA column (Phenomenex Inc.), 15 
m x 0.25 mm ID, 0.1 µm film thickness. The MS was operated in scan (mass 
range 50-420 m/z) and SIM (selected ion monitoring) mode. For quantification, 
calibration curves were generated using dilution series of standard solution 
(Phenomenex, Fluka). For most amino acids a calibration range of 0.75-675 
µM was used.127 
8.2.5 Data analysis for feature detection 
For the quantitative analysis of selected metabolites, we used QuantAnalysis 
(Bruker Daltonics). Extracted ion chromatograms (EICs) were generated for 
the metabolites of interest, using their exact mass as given in the MetaCyc 
database 128 with a mass tolerance of ±0.01 Da. Calibration curves were 
measured before each batch of biological samples. 
For the identification of unknown metabolites, we employed the ‘Find All Com-
pounds’ algorithm provided with the DataAnalysis software suite from Bruker 
Daltonics. Metabolites found with this approach were identified by a database 
search using the exact mass ±0.01 Da in MetaCyc (http://metacyc.org/) and 
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the Human Metabolome Database (HMDB) (http://www.hmdb.ca/), and by 
comparison with the ‘Generate Molecular Formula’ (GMF) function, which 
estimates the potential molecular formula for a queried mass according to its 
exact m/z value and its isotopic pattern. The ‘Find All Compounds’ algorithm is 
able to look for correlations in the detected features, thus excluding isotopes 
and adducts. However, this can be problematic for the stable isotope labeled 
standards and for closely migrating compounds. Also, the software is not able 
to align the detected features of multiple samples. Therefore, we adapted an 
open-source data analysis software (MZMine, 109) for the specific challenges 
of CE-MS analysis, i.e. we implemented the migration time correction method 
adapted from Reijenga et al. 124 as described in section 6.3.4. This allowed the 
rapid scanning of samples for additional metabolites. Alignment over multiple 
samples is possible; we included only those features in the alignment that 
were found in at least 6 out of 24 E. coli samples analyzed for every culture 
condition. The detected masses were queried as described above. The 
metabolites identified were validated by generating the corresponding EICs in 
DataAnalysis and applying the GMF tool to the molecular mass peak. When-
ever possible, the identity of metabolites was confirmed with commercial 
standards. 
8.3 Results and Discussion 
8.3.1 Metabolic profiling in E. coli - method validation by 
comparison to other analytical methods 
The optimized analytical protocol was applied to the comparative analysis of 
the E. coli wild type strain MG1655 with the double deletion mutant UdhA-
PntAB (MG1655 ΔudhA ΔpntAB). The latter is deleted for both nicotinamide 
nucleotide transhydrogenases expressed in E. coli, which leads to a substan-
tial re-routing of the metabolic flux from glycolysis to the pentose-phosphate 
pathway to meet the cellular demand for NADPH.12 We were interested in the 
effect of this alteration in the main catabolic fluxes on steady-state cellular 
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metabolite levels. Initially, both strains were cultivated in complex medium and 
harvested after they had reached the stationary phase. Harvesting, metabolite 
extraction and sample preparation were performed as described in chapter 7. 
Four independent cultures were analyzed for each strain, with three replicates 
taken from each culture. The extracts were divided into two aliquots for CE-MS 
and GC-MS analysis, respectively. Of the 20 compounds in the quantitative 
metabolite panel (see Table 2), 18 were detected above the LLOQ in the ex-
tracts. Oxaloacetate and PG were not detected above the LLOQ. The analyti-
cal variability caused by extraction and CE-TOF-MS analysis, respectively, 
was assessed separately (see Table 3). The analytical variance was deter-
mined by measuring one of the E.coli samples four times over the course of 
one sample batch. It ranged from 3.7–12.6 % for all metabolites except for 
F6P and G6P, which did not resolve well in this biological matrix. In compari-
son, Soga et al. had reported an analytical variance of 0.7-9% for a metabolite 
standard mixture using CE-TOF-MS, and an inter-day variability averaging 
30% for E. coli samples 97. Extraction variance was assessed from three inde-
pendent extractions of samples taken from one flask. It was between 8-17% 
for all metabolites except G6P, with 22.6%, which is similar to the analytical 
variance of this compound. Finally, the biological variability was determined by 
analyzing samples from four independent shake flasks for each of the two E. 
coli strains under investigation. Biological variability ranged from 3.4% to 
31.3% and exceeded in most cases the experimental error. 
To validate the CE-TOF-MS method, the E. coli samples were also subjected 
to two different GC-MS analyses: one was based on methoximation and silyla-
tion (GC-MS) for the analysis of small organic acids, while the other employed 
derivatization of primary and secondary amino groups with chloropropylfor-
mate for the analysis of amino acids (GC-(AA)-MS).127 For GC-MS the analyti-
cal variance was smaller, between 0.9-4.6% for most of the metabolites, 
except for F6P, G6P and lactate (8-12%). This concords with other reports.9 
Extraction variability was similar to CE-TOF-MS (4.1-18.9%) as was the bio-
logical variance (3.6-30.3%). The analytical variance of GC-(AA)-MS (0.6-
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11.3%) was similar to that of CE-TOF-MS, while extraction variability was 
between 9.9 – 20% for most amino acids except for glutamine (22.7%), 
proline, glycine and alanine (26.1- 29.4%), as well as tryptophan (44%). Bio-
logical variability was between 9.4-34% for most amino acids, exceptions were 
again alanine, glycine, proline, and tryptophan (35-70%). This suggested that 
extraction with 80% MeOH was not optimally suited for the latter amino acids, 
underscoring the difficulty of optimizing an analytical method for a great variety 
of metabolites. In conclusion, these findings demonstrated that the analytical 
variance of CE-MS and two different GC-MS methods was comparable, with 
GC-MS of methoximated and trimethylsilylated compounds performing slightly 
better than the other two methods.  
 
Figure 17: Comparison of the quantitative results of CE-MS vs. GC-(AA)-MS and GC-MS. 
Values are averages from 4 independent biological replicates, with 3 extracted samples per 
replicate. 
For validation purposes, the quantitative data for metabolites detected in CE-
MS and GC-MS was compared (Figure 17). Most metabolites showed an 
excellent concordance of the absolute quantities found in the cell extracts 
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(e.g., lactate, pyruvate, malate, glutamate, citrate, fumarate, P-glycerate and 
succinate).  
For AMP much higher amounts were found with GC-MS. The reason is that 
ATP and ADP are degraded to AMP under GC-MS conditions (Figure 18). 
 
Figure 18: GC-MS chromatograms of AMP-, ADP- and ATP-standards. AMP cannot be 
quantified accurately, because ADP and ATP are converted to AMP during the analysis after 
loss of one or two phosphate groups. 
For the amino acids glutamate and aspartate, which were detected by both 
CE-MS and GC-(AA)-MS, a very good correlation was observed (Figure 17). 
Of the other amino acids, many showed significant differences between the 
wild type and the mutant strain. For example, proline, contrarily to aspartate 
and glutamate, yielded six-times lower amounts in the wild type, while alanine, 
glycine and tryptophan were about two times lower. Aminoadipic acid was 
found at five times higher levels in the wild type. 
All samples from one strain (n=12) were used to test for normal distribution by 
means of the Kolmogorov-Smirnov test of goodness of fit, where a p-value 
≥0.05 indicates no deviation from normal distribution. All metabolites showed a 
normal distribution. We then applied the Student’s t-test (two-tailed, pair wise) 
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to test for significant (P<0.05) differences in metabolite levels between the two 
strains. With the exception of lactate, 2KG, G1P and NAD, metabolite levels 
differed significantly between the wild type and the mutant strain (Table 4). 
Interestingly, the levels of most metabolites of the citric acid cycle were 
significantly higher in the mutant, while the amino acids glutamate and aspar-
tate were higher in the wild type strain. 
Table 4: Metabolite levels [nmol/mg cdw] in wild type vs. PntAB-UdhA, grown in complex 
medium and harvested in stationary phase. 
 Wild type (MG1655) PntAB-UdhA  
Metabolite  [nmol/mg cdw] n=12 
 [nmol/mg cdw] 
n=12 
p-Value 
(t-test) 
Lactate 0.41±0.08 0.44±0.11 0.12 
Pyruvate 0.25±0.05 0.48±0.16 <0.001 
Citrate 0.68±0.01 42.18±1.90 <0.001 
2KG 0.28±0.05 0.30±0.03 0.2 
Succinate 0.45±0.06 0.80±0.09 <0.001 
Fumarate 0.11±0.03 0.58±0.11 <0.001 
Malate 0.27±0.11 2.04±0.30 <0.001 
Aspartate 7.92±1.13 4.24±0.31 <0.001 
Glutamate 44.50±4.30 16.94±0.57 <0.001 
G1P 0.09±0.009 0.10±0.01 0.057 
G6P 0.62±0.20 1.20±0.19 <0.001 
F6P 0.87±0.27 1.78±0.33 <0.001 
FBP 0.14±0.03 0.75±0.35 0.012 
3PG 1.62±0.36 3.37±0.61 <0.001 
Gycerol-1P 0.36±0.00 0.55±0.09 0.0013 
AMP 0.26±0.01 0.39±0.12 0.0015 
ADP 0.75±0.14 0.96±0.28 0.014 
NAD 4.63±1.15 4.25±0.44 0.22 
8.3.2 Evaluation of the robustness of observed differences in 
metabolite levels 
The results described above were obtained with E. coli cells that had been 
cultivated in complex medium. Thus, it was not clear whether the observed 
differences had resulted from altered flux distributions through the central 
carbon metabolism or whether they had been caused by interfering medium 
components. Therefore, we also grew both E. coli strains in minimal medium 
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supplemented with glucose. Samples were taken during exponential (log) and 
stationary (stat) phase to distinguish effects resulting from different growth 
phases. Four independent cultures were analyzed for each strain, with three 
replicates taken from each culture. The quantitative results are given in Table 
5. Absolute metabolite levels differ as a function of growth stage, e.g. aspar-
tate, 2KG resp. AMP. Further, cell culture medium related differences are 
found for FBP, which is only detected when cells are grown in the LB complex 
medium. Nevertheless, the absolute metabolite levels in E. coli are generally 
quite similar in cells cultured on different media and harvested at different 
growth stages. This is to be expected, because metabolite levels are 
influenced by a multitude of control mechanisms, which are able to balance 
internal and external perturbations.97 
Table 5: Metabolite levels [nmol/mg cdw] in wild type vs. PntAB-UdhA, grown in minimal 
medium and harvested in both logarithmic and stationary phase. 
  M9 Logarithmic phase  M9 Stationary phase 
 Wild type PntAB-UdhA  Wild type PntAB-UdhA  
Metabolite 
Average 
content 
[nmol/mg 
cdw], n=12 
  
Average 
content 
[nmol/mg 
cdw], n=12 
 p-Value   (t-test)  
Average 
content 
[nmol/mg 
cdw], n=12 
 
Average 
content 
[nmol/mg 
cdw], n=12 
  p-Value   (t-test) 
Lactate 6.44±2.51  1±0.38 <0.001 0.96±0.16 0.83±0.15  0.047 
Pyruvate 0.5±0.21  0.36±0.06 0.111 0.26±0.06 0.25±0.07  0.941 
Citrate 1.03±0  16±3.93 <0.001 1.87±0.67 19.8±7.87  <0.001 
2KG < LLOQ  0.06±0.05 n/a 0.48±0.25 0.54±0.26  0.645 
Succinate 0.75±0.32  1.12±0.41 0.022 0.92±0.21 1.8±0.49  <0.001 
Fumarate 0.35±0.15  0.54±0.14 0.005 0.3±0.08 0.54±0.15  <0.001 
Malate 0.29±0.21  1.02±0.2 <0.001 0.79±0.24 2.61±0.67  <0.001 
Aspartate 2.07±0.62  2.34±0.34 0.242 6.09±1.57 3.78±1.27  0.002 
Glutamate 23.1±5.57  12.3±2.81 0.002 68.9±22.6 32.4±9.1  0.004 
G1P < LLOQ  < LLOQ  0.18±0.04 0.15±0.04  0.133 
G6P 0.87±0.32  2.5±0.69 <0.001 0.46±0.18 0.3±0.13  0.017 
P-Glycerate 3.58±1.11  2.07±0.33 0.007 1.94±0.26 2.12±0.51  0.298 
Gycerol-1P 3.23±3.8  0.51±0.22 0.027 1.84±1.26 0.68±0.37  0.016 
AMP 0.84±0.19  0.59±0.09 <0.001 0.29±0.04 0.22±0.05  0.002 
ADP 0.4±0.14  0.39±0.11 0.363 0.69±0.12 0.34±0.06  <0.001 
NAD 2.04±0.79  3.03±0.71 0.004 4.26±0.73 3.77±1.08  0.22 
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In Table 6, the ratios of metabolite levels in wild type over the PntAB-UdhA 
strain under the different growth conditions are given. Glutamate levels were 
consistently higher (1.9-2.6) in the wild type under the three different 
conditions, while malate, succinate, fumarate and citrate (all part of the TCA) 
were much higher in the transhydrogenase deficient strain. Interestingly, 
aspartate was only elevated in wild type cells harvested during stationary 
phase, independent of the medium. NAD levels were constant in stationary 
phase, but reduced in the wild type strain during exponential growth. This 
probably mirrors an increased conversion to NADP, which is required for the 
biosynthetic reactions needed for cell division and growth. 
Table 6: Relative changes in metabolite levels in wild type over PntAB-UdhA under different 
growth conditions. 
Metabolite LB (stationary) M9 (exponential) M9 (stationary) 
Lactate 0.9 6.4* 1.2* 
Pyruvate 0.5* 1.4 1 
Citrate 0.016* 0.06* 0.09* 
2-Ketoglutarate 0.9 n.d.a) in wt * 0.9 
Succinate 0.6* 0.7* 0.5* 
Fumarate 0.2* 0.7* 0.6* 
Malate 0.1* 0.3* 0.3* 
Aspartate 1.9* 0.9 1.6* 
Glutamate 2.6* 1.9* 2.1* 
G1P 0.9 n.d.a) 1.2 
F6P 0.5* 0.3* 1.6* 
FBP 0.2 n.d.a n.d.a) 
P-Glycerate 0.5* 1.7* 0.9 
Gycerol-1P 0.7* 6.4* 2.7* 
AMP 0.7* 1.4* 1.3* 
ADP 0.8 1.0 2* 
NAD 1.1 0.7* 1.1 
* Significantly different between strains (p<0.05 in Student’s t-test) 
a) Below LLOQ 
8.3.3 Metabolic fingerprinting of E. coli 
The above results demonstrated the ability of our approach to yield validated 
quantitative data on a number of selected metabolites. However, the 
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challenges of modern systems biology often make it difficult to define in 
advance all of the metabolites that might be of interest in a certain biological 
context. To this end we made use of the TOF-MS‘s high mass accuracy and 
the fast scan speed over the complete mass range of 40-800 Da. The major 
problem in this regard is to extract meaningful conclusions from the huge 
amount of data collected in each electrophoretic run. Data extraction was 
performed using MZMine, an open-source program we adapted to the specific 
challenges of CE-MS, as described in section 2.8. With this approach more 
than 600 features, characterized by mass and MT and representing potential 
metabolites, were extracted from the electropherograms. A database search of 
the features with the exact mass ±0.01 Da in MetaCyc (http://metacyc.org/) 
and the Human Metabolome Database (HMDB) (http://www.hmdb.ca/) yielded 
207 hits. After validation with the ‘Generate Molecular Formula’ tool integrated 
in the program Data Analysis from Bruker Daltonics, we identified 150 
metabolites by their exact mass and their molecular formula, 71 of which could 
be confirmed by a reference standard (Table S1, Appendix). About 50 prelimi-
narily identified metabolites had to be excluded, because no formula could be 
generated. Twenty-three were found to be either isotopes of abundant 
metabolites or multiply charged species. For most of the others, generating a 
reasonable formula was not possible due to interferences in the isotope 
peaks, either by overlapping compounds or a high background. These findings 
demonstrated the importance of integrating the identification of metabolites via 
their exact mass with additional quality control parameters. These included 
their molecular formula, corrected migration time and, if possible, comparison 
with a commercially available standard. Using the criteria of exact mass, 
molecular formula and migration time, we have as yet not assigned incorrectly 
a metabolite that could not be confirmed by measuring the corresponding 
standard substance. 
Peak detection and peak area integration in MZMine are done automatically. 
Although integration markers cannot be altered manually, we found a very 
good correlation for the wt:PntAB-UdhA ratios between the metabolites 
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quantified with QuantAnalysis and the MZMine derived data for most analytes. 
Exceptions were the hexose-phosphates, which are not resolved in MZMine, 
and pyruvate and 2KG in M9 log, which are present at low concentrations. 
Less stringent constraints for automated peak detection might give better 
results for low-abundance metabolites. In turn, however, this may lead to an 
increased number of false-positive features. We also did a semi-quantitative 
analysis in terms of peak area relative to internal standard for 12 randomly 
chosen additional metabolites that were identified in the extract and again the 
ratios were highly similar to the ones obtained with MZMine (Table 7). 
Table 7: Comparison of the metabolite ratios in wild type over PntAB-UdhA obtained by the 
signal integration programs QuantAnalysis and MZMine. 
  LB (Stationary)   M9 (Exponential)   M9 (Stationary) 
Metabolite Quant Analysis MZMine   
Quant 
Analysis MZMine   
Quant 
Analysis MZMine 
Lactate 0.9 1.3  6.4* 4.07*  1.2* 1.3* 
Pyruvate 0.5* 0.3*  1.4 n.d.a)  1 0.3 
2KG 0.9 1.0  n.d.a) in wt 0.6  0.9 1.1 
Succinate 0.6* 0.7*  0.7* 0.7*  0.5* 0.5* 
Glutamate 2.6* 2.8*  1.9* 2.1*  2.1* 2.3* 
G1P/F6Pb) 0.9/0.5* 0.5*  n.d.a)/0.3* 0.4*  1.2/1.6* 1.4* 
ADP 0.8 0.8  1.0 1.0  2* 2.0* 
NAD 1.1 0.8  0.7* 0.7*  1.1 1.1 
Benzoic acid 2.4* 2.7*  2.1* 2.2*  1.1 1 
cis-Aconitic acid 0.03* 0.01*  PU only* 0.1*  0.3* 0.2* 
Glucuronate 0.3* 0.04*  PU only* 0.1*  PU only* 0.1* 
Glutamine 1.6 n.d.a)  0.7* 0.3*  1.6* 1.7* 
Glutarate 1.2 1.2  0.7* 0.6*  2.4* 2.2* 
Glutathione 1.9* 1.9*  1.6* 1.6  1.2* 1.4* 
NADP 1.8* 1.5  1.1 1.6  3.2* 5* 
Orotic acid PU only* 0.3*  wt only* 11.6*  wt only* n.d.a) 
Ribose-5-P 0.7* 0.5  2.2 n.d.a)  0.9 0.7 
Sedoheptulose-7-P 0.6* 0.6*  1.1 1  1.1 1.1 
Tartaric acid 1.1 0.6  1.2 n.d.a)  n.d.a) n.d.a) 
UDP-D-glucose 1.1 0.8*  1.3* 1.2  2.6* 2.4* 
* Significantly different between strains (p<0.05 in Student’s t-test) 
a) Below LLOQ 
b) G1P, F6P and G6P are not separated in the automated MZMine analysis 
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Although the electrophoretic conditions had been optimized for the separation 
of negatively charged metabolites, it proved possible to detect even positively 
charged compounds, as they were swept to the capillary outlet by the EOF 
and the pressure applied after the electrophoretic separation for washing and 
conditioning. Despite their incomplete resolution, they could be in part quanti-
fied accurately as exemplified for such metabolites as valine, lysine, proline, 
nicotinamide and glucose (in comparison with GC-MS derived data, data not 
shown). 
In summary, we found higher levels of metabolites of the pentose-phosphate 
pathway (PPP) and the citric acid cycle in the transhydrogenase-deficient 
mutant strain. The differences in PPP were only seen in LB medium. In mini-
mal medium, the PPP intermediates were detected at low levels and, there-
fore, the resulting higher standard deviations might obscure any significant 
differences. The increased abundance of PPP intermediates in the deletion 
mutant might indicate an increased flux of substrate through these pathways 
to fulfill the cell’s need for NADPH, which is a cofactor in many reductive syn-
thetic reactions such as fatty acid and nucleic acid synthesis. NADPH is 
produced in the PPP by the enzyme 6-phospho-D-gluconate:NADP+ 2-
oxidoreductase and in the citrate cycle by the enzyme isocitrate:NADP+ 
oxidoreductase. In addition, we consistently found increased levels of reduced 
glutathione (GSH) in the wild type strain under all conditions. This might be 
due to the decreased availability of NADPH, which is necessary for the reduc-
tion of glutathione disulfide (GSSG) to GSH by the enzyme glutathione re-
ductase. Along the same line the differences in glutamate levels could be 
explained. Glutamate is synthesized from 2KG by the enzyme glutamate syn-
thase, which is NADPH dependent. Lower levels of NADPH could thus lead to 
lower reaction rates. A summary of the data is given in Figure 19, showing 
significant differences in the detected metabolite levels (t-test, P<0.05) inte-
grated into a central carbon metabolism pathway map. 
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Figure 19: Diagram of the central carbon metabolism. Metabolites that were quantified with 
calibration curves are marked in bold, while metabolites measured semiquantitatively are 
marked in bold and italic. Metabolites that are found in higher concentrations in the wild type 
are indicated with an arrow pointing up; higher concentrations in the PntAB-UdhA strain are 
indicated with an arrow pointing down; the growth conditions are abbreviated as LB-S, com-
plex medium stationary phase; M9-S, minimal medium stationary phase; and M9-L, minimal 
medium logarithmic phase. 
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8.3.4 The validated CE-TOF-MS method in the context of recent 
developments in metabolome analysis 
We compared our E. coli metabolite data with a CE-TOF-MS method for the 
analysis of negatively charged metabolites using commercial coated SMILE 
capillaries and positively charged metabolites as well as nucleotides, sepa-
rated in untreated fused silica capillaries employing different BGE and precon-
ditioning.97 In total, Ishii et al. observed 61 of the 150 high-confidence 
identifications reported in our study (40.7%). If only negatively charged me-
tabolites were considered, we detected 29 of 62 reported by Ishii et al. 
(46.8%). However, these numbers increased to a concordance of about 70% 
(26/38) upon comparison of metabolites that had been found in at least 20% of 
replicate samples. The differences in metabolites observed in the two studies 
might be due to the slightly different genetic backgrounds of the wild type 
strains used, namely MG 1655 vs. BW 25113, and the different culture 
conditions employed (steady-state bioreactor vs. shake flask). 
In comparison to other methods developed for the quantitative analysis of the 
intermediates of the central carbon metabolism, CE carries the advantages 
that only minute sample amounts are required and that there is no need for 
pre-column derivatization of analytes. A disadvantage is the variability of mi-
gration times, but there are, as reported here, effective ways of correcting for 
such variation. The GC-MS methods we used in this project yielded LODs 
comparable to those of CE-TOF-MS (data not shown). LC-MS/MS based 
methods achieve lower LODs, typically in the concentration range of 1-50 nM 
11 as is also shown in the next chapters. However, one has to keep in mind 
that for a TQ-MS to yield the highest possible sensitivity, the instrument has to 
be operated in multiple-reaction monitoring (MRM) mode, which requires prior 
knowledge of the analytes. Screening for additional metabolites would there-
fore require an additional analytical run, preferably using a TOF-MS, since 
quadrupole instruments are less sensitive in scan mode and give only unit 
mass resolution, which leads to a high number of possible metabolite hits.  
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9 Method development for rapid lactate measurement 
9.1 Introduction 
The generation of lactate from pyruvate is one possibility for cells to regen-
erate NAD, which is consumed during glycolysis when glyceraldehyde-3-
phosphate is converted to 1,3-bisphosphoglycerate. Lactate is secreted to the 
cell medium and accumulates there. Alterations in lactate levels can yield in-
formation on alterations in the central carbon metabolism, for example the 
production of lactate is associated with the rapid growth of tumor cells.129 In 
several projects we are especially interested in the excretion or uptake of 
lactate and its isotopes. For these projects we wanted to develop a method 
that is able to quantify lactate and all possible isotopes of this compound. The 
main focus during method development was on analysis speed, because we 
needed a method that was able to screen a high number of samples in a 
reasonable amount of time. 
Method development was based on a protocol described by Luo et al. 11 for 
IP-LC-MS/MS. This method is based on the formation of ion pairs between the 
negatively charged analytes and the buffer additive tributylamine (TBA), which 
allows their separation on a polar endcapped reversed phase column. Very 
good resolution of a number of charged compounds was reported, however 
the complete method takes 90 minutes for the analysis of one sample. We 
could shorten the method to a total analysis time of 16 minutes, while still re-
taining the separation of lactic acid and several other metabolites of interest, 
such as pyruvate and the hexose phosphates. The quantitative capabilities of 
this approach are demonstrated. 
The analysis of lactate uptake into cells of the immune system was published 
in 114. 
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9.2 Material and Methods 
9.2.1 IP-LC-MS/MS 
An Agilent 1200 SL HPLC system was used for liquid chromatography. The 
separation was performed on a Synergi Hydro-RP column (150 mm x 2.0 mm 
I.D., 4 μm particles, 80 Å pore size). Eluent A was 10 mM tributylamine (TBA), 
15 mM acetic acid (pH 4.95), eluent B was pure methanol. The optimal flow 
rate was found to be 350 μl/min, with the column held at a constant tempera-
ture of 50ºC. The optimized gradient conditions were as follows: 0 – 7 min 
from 0% to 90% B and hold for 3 min at 90% B. Before every run the column 
was equilibrated at 100% A for 6 minutes. 
The HPLC system was directly coupled to a 4000 QTRAP mass spectrometer 
(ABI/MDS Sciex, Concord, Canada). The MS was operated in negative ion 
mode with selected reaction monitoring (SRM). Source settings were as 
follows: IonSpray Voltage (IS) -3700 V, auxiliary gas temperature (TEM) 
350ºC; curtain gas (CUR) nebulizer gas (GS1), auxiliary gas (GS2) were set to 
10, 50 and 50 (arbitrary units), respectively; collision gas (CAD) was set to 
medium. The entrance potential (EP) was set to -10 V for each compound. 
Declustering potential (DP), collision energy (CE) and collision cell exit poten-
tial (CXP) were optimized for lactate and pyruvate, as well as the MS/MS 
fragment pattern (see Table 9 in the next chapter). Compound specific 
optimization was performed by direct infusion of a 10 μM solution of each 
standard substance in water/methanol 50:50 (v/v), containing 10mM TBA and 
15mM acetic acid. The infusion was performed at a flow rate of 10 μl/min 
using a model 11 PLUS syringe pump (Harvard Apparatus, Holliston, USA). 
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9.3 Results and Discussion 
9.3.1 Method development for fast lactate measurement 
We modified the IP-LC-MS/MS method described by Luo et al. 11 for the rapid 
analysis of lactate and pyruvate in biological samples. Using the original 
gradient, lactate, pyruvate and several other metabolites are eluted from the 
column under isocratic conditions at 100% A. However, the isocratic part of 
the method including washing and equilibration takes about 30 minutes. In a 
first step, we increased the flow rate from 200 µL/min to 350 µL/min.  A 
sample chromatogram of the isocratic run at 350 µL/min of a mixture of 
metabolite standards is shown in Figure 20 a. In order to further decrease total 
analysis time, different gradients and their effect on the chromatographic 
behavior of lactate were tested (Table 8). 
Table 8: Effect of different gradient conditions on the chromatographic behavior of lactate 
Gradient Peak Area [x106] FWHM RT [min] 
100% A, 15 min 0.47 0.28 8.9 
95% A, 15 min 0.76 0.26 6.7 
0 --> 25% B, 15 min 1.02 0.19 7.3 
0 --> 50% B, 15 min 1.48 0.17 6.6 
0 --> 60% B, 7 min 1.91 0.15 6.0 
0 --> 90% B, 11 min 1.95 0.14 6.1 
0 --> 90% B, 7 min 2.19 0.14 5.7 
The optimal gradient was 0 Æ 90% B in 7 minutes, thus reducing the run time 
by half to an injection every 16 minutes. A chromatogram under optimized 
gradient conditions is shown in Figure 20 b. The benefits of the fast gradient 
as compared to the isocratic separation for lactate were as follows: retention 
decreased from 8.9 min to 5.7 min; FWHM was halved from 0.28 min to 0.14 
min; while the area increased by a factor of about 4, from 2.73E+05 to 
1.23E+06.  
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Figure 20: Effect of gradient optimization on the separation of selected compounds. 
9.3.2 Uptake of lactic acid into different immune cell populations 
The modified IP-LC-MS/MS method was applied to the measurement of 
lactate uptake into different immune cell populations, such as cytotoxic T-
lymphocytes (CTLs), T-helper cells, regulatory T-cells and monocytes. The 
lactate isotopomer [3-13C]lactate was added in varying concentrations to the 
different immune cell cultures. Cells were extracted and the concentration of 
labeled lactate in the cell extracts was determined. By this approach, uptake of 
lactic acid into CTLs and its increase upon extracellular acidification was 
demonstrated (Figure 21).114 
A 
B 
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Figure 21: Uptake of 13C-labelled lactate by CTL. CTL were incubated for 30 minutes with 
20mM external 13C-lactate in the presence or absence of HCl (n=4). Endogenous lactate and 
the uptake of exogenous lactate was determined in the cell lysates by CE-TOF-MS.114  
Furthermore, the method was used to study the effects of lactic acid on mono-
cytes. It was shown that lactic acid inhibits TNF-alpha secretion by 
suppressing glucose metabolism in monocytes.130  
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10 Method development for targeted metabolite 
analysis using rapid resolution IP-LC-MS/MS 
10.1 Introduction 
The method described by Luo et al. 11, while achieving a high resolution of 
critical isomers, e.g., G6P and F6P, takes 90 minutes. This is not suitable for 
the high-throughput analysis of the dozens to hundreds of biological samples 
typically required for a sound statistical analysis. The goal in this subproject 
was to substantially accelerate the analysis, while still retaining acceptable 
resolution of critical isomers. This was implemented in several steps: (i) use of 
smaller particles (2 μm) to allow shorter columns and increased flow rate; (ii) 
optimization of gradient conditions with regard to short retention time, 
resolution, peak shape and sensitivity; (iii) robust quantification of selected 
metabolites by introduction of stable isotopes. 
The Van Deemter curve relates the height of a theoretical plate (H) to the 
linear velocity of the mobile phase (u). The smaller H the better the separation, 
because more peaks can be resolved on a column (N=L/H). The resolution is 
directly proportional to the square root of N, thus the smaller H the better the 
resolution. The factors that mainly influence H are the size of the stationary-
phase particles and the diffusion coefficient. From the Van Deemter plot (see 
Figure 7) it becomes clear, that the smallest values for H are reached at a 
certain flow rate optimum. It was shown, that this optimum is substantially 
dependent on the particle size; it is shifted to larger flow rates with decreasing 
particle size. Also, the optimum flow region becomes broader under these 
conditions, allowing the use of higher flow rates. 
We evaluated the benefits of the rapid resolution approach for the IP-LC-
MS/MS analysis of intermediates of the central carbon metabolism and estab-
lished the quantitative capabilities of the optimized method. The method was 
further validated for biological applications by measuring E. coli cell extracts.  
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10.2 Material and Methods 
10.2.1 LC-MS/MS 
An Agilent 1200 SL HPLC system was used for liquid chromatography. The 
separation was performed on a YMC-Ultra HT Hydrosphere C18 column (100 
mm x 2.0 mm I.D., 2 μm particles, 120 Å pore size). Eluent A was 10 mM 
tributylamine (TBA), 15 mM acetic acid (pH 4.95), eluent B was pure metha-
nol. The optimal flow rate was found to be 380 μl/min, with the column held at 
a constant temperature of 40ºC. The optimized gradient conditions were as 
follows: 0 – 5 min hold at 100% A, 5 – 25 min from 0% to 90% B and hold for 5 
min at 90% B. Before every run the column was equilibrated at 100% A for 7 
minutes. 
The HPLC system was directly coupled to a 4000 QTRAP mass spectrometer. 
The MS was operated in negative ion mode with selected reaction monitoring 
(SRM). Source settings were as follows: IonSpray Voltage (IS) -3700 V, 
auxiliary gas temperature (TEM) 350ºC; curtain gas (CUR) nebulizer gas 
(GS1), auxiliary gas (GS2) were set to 10, 50 and 50 (arbitrary units), respec-
tively; collision gas (CAD) was set to medium. The entrance potential (EP) was 
set to -10 V for each compound. Declustering potential (DP), collision energy 
(CE) and collision cell exit potential (CXP) were optimized for each compound, 
as well as the MS/MS fragment pattern (Table 9). Source settings and com-
pound specific optimization were performed by direct infusion of a 10 μM solu-
tion of each standard substance in water/methanol 50:50 (v/v), containing 
10mM TBA and 15mM acetic acid. The infusion was performed at a flow rate 
of 10 μL/min using a model 11 PLUS syringe pump. Additional SRM transi-
tions were analyzed for all possible isotope distributions of selected com-
pounds. Care was taken to keep the scan time for each compound at or above 
30 ms. In order to still record enough data points for each peak (cycle time < 
1.5 s), the run was subdivided into 4 periods, which were selected according 
to retention times of the compounds of interested. 
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Table 9: Optimized SRM parameters for measured metabolites 
Metabolite Mass [Q1] Mass [Q3] Main product ion DP [V] CE [V] CXP [V] 
AMP 346 79 [PO3]- -88 -57 -11 
Succinate 117 73 -CO2 -43 -16 -10 
Malate 133 115 -H2O -20 -15 -18 
Lactate 89 43 -HCOOH -47 -18 -5 
Pyruvate 87 43 -CO2 -42 -13 -4 
P-glycerate 185 97 [H2PO4]- -45 -21 -14 
Aspartate 132 88 -CO2 -25 -17 -13 
FBP 339 97 [H2PO4]- -58 -29 -10 
G6P 259 79 [PO3]- -62 -57 -22 
F6P 259 79 [PO3]- -57 -62 -11 
Glutamate 146 102 -CO2 -51 -19 -16 
NAD 662 540 -Nicotinamide -60 -19 -12 
NADP 742 620 -Nicotinamide -53 -22 -13 
Fumarate 115 71 -CO2 -45 -11 -10 
Glycerol-P 171 79 [PO3]- -55 -21 -11 
2-Ketoglutarate 145 101 -CO2 -35 -12 -16 
ADP 426 79 [PO3]- -80 -88 -3 
cis-Aconitate 173 85 -2CO2 -30 -17 -12 
Ribose-5P 229 97 [H2PO4]- -52 -18 -14 
DHAP 169 97 [H2PO4]- -32 -14 -11 
Lactoylglutathione 378 306 Glutathione -78 -22 -15 
Methylglyoxal 71 43 -CO -80 -13 -4 
Glyoxylate 73 45 -CO -65 -13 -4 
Acetyl-CoA 808 79 [PO3]- -115 -120 -11 
10.2.2 Samples and sample preparation 
Cultivation on minimal medium and extraction of E. coli cells was performed as 
described above. The internal standard solution was the same as described 
below in the quantification section. 
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10.2.3 Quantification 
Absolute quantitation of 21 different metabolites, including 2KG, F6P, G6P, 
FBP, AMP, ADP, NAD, NADP, glutamate, aspartate, glycerol-1P, glycerol-2P, 
fumarate, cis aconitate, lactate, pyruvate, malate, succinate, citrate, 3PG and 
ribose-5P was accomplished with a dilution series of an equimolar (5 mM) 
aqueous stock solution of all standards (= standard mix), to which 10 resp 2 
μM each of the extraction and internal standard compounds [2,3,3,3-
2H4]lactate, [U-2H]succinate, [2,3,3-2H3]malate, [2,3,3,4,4-2H5]glutamate, [U-
13C]fumarate, [U-13C]pyruvate, [U-13C]glucose-1-phosphate and [U-13C, U-
15N]AMP had been added. Prior to analysis of biological samples, 15 
calibration points were generated over a concentration range of 2.5 nM -100 
μM. Spectral peak integration was done with Analyst 1.4.2 (Applied 
Biosystems) following normalization of the peak areas of the standards to the 
area of the closest migrating internal standard. Concentrations were then 
inferred from the calibration curves. Stability of measurement was checked by 
periodical injection of a quality control sample between biological samples. 
10.3 Results and Discussion 
10.3.1 Optimization of flow rate – Van Deemter Plots 
Van Deemter plots are generated under isocratic conditions. We, therefore, 
used 100% eluent A to elute several standard compounds (aspartate, gluta-
mate, lactate, G6P, F6P and pyruvate) that can be separated with this solvent 
strength. The flow rate was ramped from 100 μL/min to 400 μL/min in incre-
ments of 50 μL/min. It would have been interesting to test lower flow rates, but 
this was not possible in a stable fashion with the LC pump used. At higher flow 
rates the pressure was quite close to the upper pressure limit of the column. 
Figure 22 depicts the experimentally determined Van Deemter plots for 
selected compounds.  
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Figure 22: Van Deemter plots for different compounds that are eluted under isocratic condi-
tions at 100% A. 
It is interesting, that the effect of the flow rate on H differs for compounds with 
different k-values. For glutamate, H does not change at higher flow rates. The 
reason for this might be that glutamate is very weakly retained under the 
applied conditions and, thus, is not much affected by changes in flow rate. 
However, the increase in flow rate results in a proportional decrease in 
retention time and peak width, i.e. a fourfold increase in flow rate from 100 to 
400 µL/min results in a roughly fourfold reduction in retention time and peak 
width (Table 10).  
Table 10: Effect of flow rate changes on retention time and peak width. 
 Glutamate Glucose-6P  Lactate 
Flow rate u 
[μl/min] 
RT 
[min] 
FWHM 
[min] 
RT 
[min] 
FWHM 
[min]  
RT 
[min] 
FWHM 
[min] 
100 8.0 0.22  12.3 0.46  13.0 0.34 
150 5.4 0.15  8.2 0.28  8.7 0.21 
400 2.2 0.07  3.3 0.10  3.5 0.09 
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The increase in efficiency at higher flow rates allows for the improved resolu-
tion of isobaric intermediates. These are glucose-6-phosphate (G6P), fructose-
6-phosphate (F6P) and glucose-1-phosphate (G1P) respectively glycerol-1P 
and glycerol-2P. As can be seen from Figure 23, the resolution increases for 
flow rates up to 200 μL/min and remains at that level for higher flow rates, 
even though retention times decrease by 50%.  
 
Figure 23: Effect of flow rate on the resolution of critical pairs of isobaric glucose metabolites. 
G1P was not used in the standard mix during further analysis, because the 
hexose-phosphates have very similar calibration parameters and G1P was not 
found previously in E. coli samples grown on minimal medium and harvested 
during exponential growth as described in chapter 8.3.2 and 83. 
10.3.2 Optimization of gradient conditions 
A number of different gradient conditions were tested (Table 11) in order to 
find an optimized method that allows for the fast and sensitive detection of the 
metabolites of interest. It was clearly seen that speeding up the gradient led to 
narrower peaks, which increased peak area and, thus, sensitivity. Neverthe-
less, we kept the initial isocratic plateau at 100% A, albeit for a shortened 
period of time, in order to maintain the high resolution of isobaric compounds 
such as the hexose- and pentose-phosphates as well as the glycerol-
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phosphates. As already seen for lactate and pyruvate, a steeper gradient had 
a positive effect on FWHM and thus signal intensities for most metabolites 
(data not shown). Gradient RR9 was finally chosen for subsequent experi-
ments after a final optimization step for several ion source parameters (CUR, 
TEM). The optimized method amounted to a total run time of 37 minutes, 
which results in a reduction of total analysis time by 59% as compared to the 
method initially described by Luo et al. 
Table 11: Gradient conditions used for gradient optimization in rapid resolution IP-LC-MS/MS. 
Equilibration was performed for 10 min before each run with the initial solvent conditions. 
Gradient 
name Gradient conditions 
RR 1 0-15’: 100Æ80% A; -35’: 80Æ65% A; -45’: 65Æ40% A; -50’: 40Æ10% A; -55’: 10% A 
RR 2 0-5’: 100Æ80% A; -35’: 100Æ10% A; -40’: 10% A 
RR 3 0-5’: 100% A; -10’: 100Æ85% A; -20’: 85Æ70% A; -35’: 70Æ10% A; -40’: 10% A 
RR 4 0-5’: 100% A; -10’: 100Æ85% A; -15’: 85Æ75% A; -35’: 75Æ10% A; -40’: 10% A 
RR 5 0-5’: 100% A; -10’: 100Æ85% A; -20’: 85Æ70% A; -30’: 70Æ10% A; -35’: 10% A 
RR 6 0-5’: 100% A; -10’: 100Æ85% A; -15’: 85Æ75% A; -25’: 75Æ10% A; -30’: 10% A 
RR 7 0-5’: 90% A; -20’: 90Æ10% A; -25’: 10% A 
RR 8 0-5’: 100% A; -10’: 100Æ85% A; -15’: 85Æ70% A; -25’: 70Æ10% A; -30’: 10% A 
RR 9 0-5’: 100% A; -25’: 100Æ10% A; -30’: 10% A 
This substantial reduction in total analysis time represents a very important 
prerequisite for the robust analysis of the large batches of biological samples 
that typically have to be investigated in system biological studies. 
10.3.3 Evaluation of quantitative capabilities 
For the absolute quantification of selected metabolites of interest, calibration 
curves were generated. To that end, an equimolar mixture of metabolites of 
interest was diluted serially over a concentration range of 100 μM to 0.1 nM. 
Calibration curve parameters as well as LOD and limits of quantitation are 
presented in Table 12.  
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Table 12: Calibration curve parameters for the optimized RR-IP-LC-MS/MS method. 
Metabolite RSQ LOD [nM] LLOQ [nM] ULOQ [μM] 
Variance, intra-day (%) 
25 μM / 500 nM 
2KG 0.997 50 250 100 5.5 / 8.6 
ADP 0.9946 10 250 100 2.2 / 1.5 
AMP 0.9995 25 50 100 1.7 / 1.4 
Aspartate 0.9987 0.5 1 100 0.7 / 0.3 
cis Aconitate 0.9966 25 50 100 1.4 / 2.5 
F6P 0.9971 1 2.5 50 0.7 / 0.5 
FBP 0.9416 5 100 100 2.9 / 2.0 
Fumarate 0.9985 10 50 100 1.1 / 1.7 
G6P 0.9978 2.5 5 50 1.4 / 1.2 
Glutamate 0.9959 1 2.5 50 0.5 / 0.3 
Glycerol-1P 0.9976 2.5 5 100 0.5 / 1.3 
Glycerol-2P 0.9987 2.5 5 100 0.9 / 2.7 
Lactate 0.9969 50 100 100 2.1 / 4.0 
Malate 0.9967 10 25 100 0.5 / 1.6 
NAD 0.9953 0.2 2.5 50 1.4 / 1.1 
NADP 0.997 5 25 100 0.9 / 1.3 
P-Glycerate 0.9987 5 50 100 1.5 / 0.7 
Pyruvate 0.9995 250 500 100 1.1 / 6.7 
Rib-5P 0.9981 1 2.5 50 0.6 / 0.9 
Succinate 0.9964 25 50 100 1.0 / 1.4 
The LOD was defined as the concentration, at which a compound can be 
detected with a signal-to-noise (S/N) of ≥3. The LLOQ and ULOQ were 
defined according to the FDA Guide for Bioanalytical Method Validation 126 as 
the lowest and highest points of the calibration curve, respectively, at which a 
compound is measured with an accuracy between 80-120%. Intra-day 
reproducibilities were evaluated by consecutive injections of standards at two 
different concentrations. Average RSDs (n=5) were 1.4% (0.5–5.5%) for the 
25 μM standard and 2.5% (0.3-11.3%) for the 500 nM standard. Inter-day 
reproducibilities were evaluated by measuring standards and biological 
samples several times over the course of several sample batches for 
approximately three days. Average RSDs (n=5) were 10.8% for the E. coli 
sample, 4.2% for the 25 μM standard and 9.2% for the 500 nM standard. 
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Evaluation of the inter-day reproducibility shows the beneficial effect of using 
isotope-labeled internal standards. Upon comparison of the average repro-
ducibilities for 20 different metabolites that were contained in the standard mix 
and detected in the E. coli samples, it was clearly seen that they were about 2-
fold smaller for the metabolites that were normalized by their corresponding 
stable isotopes as compared to the other analytes (Figure 24).  
For the analysis of large sample batches, several quality control (QC) samples 
were interspersed throughout the measurement to ensure analytical stability.83 
If these QC samples failed to meet the established acceptance criteria 83, 126, 
measurement of the associated samples was repeated. These steps ensure 
that reliable quantitative data is generated and that the method can be applied 
over an extended period of time to large sample batches. 
 
Figure 24: Intra-day reproducibility. Different samples were analyzed multiple times (n=5) 
over the course of 3 days. The average relative standard deviations (RSDs) for selected 
metabolites are shown.  + IS: average RSD for metabolites with a matching stable isotope-
labeled standard included. –IS: average RSD for metabolites that are normalized by a different 
standard. 
Compared to methods based on AEC-MS/MS, the IP-LC-MS/MS approach 
has the advantage of detection limits that are 3-4 orders of magnitude lower.13, 
70 Therefore, more metabolites, including those that do not accumulate in the 
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cell, can be detected. While HILIC is well suited for the separation of polar 
analytes, average RSDs of 13% have been reported for the repeated analysis 
of cell extracts 5 and also in a direct comparison to RP-HPLC larger 
variabilities for peak areas have been observed.131 
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11 Analysis of glycolytic flux distribution in E.coli  
11.1 Introduction 
Flux analysis is a potent tool for the quantitative analysis of biochemical 
reaction networks, thus providing information on cellular regulation at the 
metabolic level.13, 84, 132 Different strategies based on hyphenated mass spec-
trometry (MS) or nuclear magnetic resonance (NMR) have been used to ana-
lyze and quantify intracellular fluxes and metabolic networks.85 
The most common approach consists of feeding the cells a labeled substrate, 
usually 13C labeled glucose or glutamine, and then analyzing the label distri-
bution, either in proteinogenic amino acids or in metabolic intermediates. The 
analysis of labeled amino acids is commonly done by GC-MS 86, 87, 133 after 
complete hydrolyzation of the intracellular proteins.  
The second approach to metabolic flux analysis is the direct measurement of 
labeling distributions in intermediates of the central carbon metabolism. The 
analysis of flux distribution between glycolysis and PPP was performed by 
GC-MS measurement of lactate and ribose labeling, derived from [1,2-13C2] 
glucose.88, 89 Isotopomers of intracellular metabolites in E. coli were also 
measured by CE-TOF-MS 90 and compared with data from GC-MS analysis of 
proteinogenic amino acids. The correlation between the two methods was 
good, remaining differences were contributed to alterations in labeling 
distribution between precursors and amino acids as well as influences from 
flux modeling.90 Another common method to analyze label distribution in se-
lected intracellular metabolites is NMR.134-136 The advantage of NMR in flux 
analysis is its ability to provide positional information on label distribution. 
However, high amounts of sample are required for 13C-NMR approaches, 
which is the reason for increasing efforts being placed on the development of 
MS-based methods for flux analysis. 
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GC-MS based flux analysis raises several problems due to the need for deri-
vatization, i.e. the addition of silica moieties, which contain a substantial frac-
tion of natural isotopes 12, 86 and the high degree of fragmentation caused by 
electron impact ionization. Hence, a method that does not require derivatiza-
tion but still yields information on positional distribution of isotopes would be of 
high value for the reliable acquisition of flux data. There are several reports on 
the use of LC-MS based methods in the context of flux analysis. An IP-LC-
MS/MS based method was used to study the effect of a short glucose pulse in 
E.coli applying ultra-fast sampling.92 Anion-exchange chromatography tandem 
mass spectrometry was used to evaluate mass isotopomer distributions of 
primary metabolites, which was subsequently fitted with a model to yield 
metabolic flux data.93 A method for flux analysis in fed batch cultures by 
measuring intracellular free amino acids was described.94 However, amino 
acids had to be derivatized prior to LC-MS/MS in order to increase their 
ionization efficiency. 
Comprehensive flux analysis requires the modeling of all possible reactions 
encountered in the system of interest. However, it is often sufficient to roughly 
estimate changes in the relative flux of glucose into the direction of glycolysis 
and PPP. The second aim of this study was, thus, to develop and validate a 
method that allows a fast and simple evaluation of shifts in the upper part of 
the central carbon metabolism. We decided to use excreted lactate as a read-
out, since it is produced by numerous organisms under many different condi-
tions in sufficient amounts. To test our method we used E. coli strains with 
different rates of glycolysis vs. PPP 12 that have already been described in 
chapter 8. With this system we evaluated the ability of our approach to esti-
mate the flux distribution between glycolysis and PPP from the analysis of 
extracellular lactate. In addition, we evaluated labeling distribution in other 
intermediates of the central carbon metabolism, in order to detect alterations 
in the TCA and related pathways. 
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11.2 Material and Methods 
11.2.1 LC-MS/MS  
LC-MS/MS was performed as described in the previous chapter. Additional 
SRM transitions were analyzed for all possible isotope distributions of selected 
compounds (Table 13). Care was taken to keep the scan time for each com-
pound at or above 30 ms. In order to still record enough data points for each 
peak (cycle time < 1.5 s), the run was subdivided into 4 periods, which were 
selected on basis of the retention times of compounds of interest. 
11.2.2 Bacterial strains and growth conditions 
The E. coli wild type strain MG1655 and its mutant PntAB-UdhA were cultured 
at 37ºC in 250-mL shake flasks containing 30 mL minimal (M9) medium 
supplemented with 3 g/L glucose. An aliquot of an overnight culture 
corresponding to an OD of 0.1 in 30 mL (V1) was taken and centrifuged (5 
min, 4500 rpm at 4°C) to separate the cells from the medium. The cell pellet 
was washed three times with 2 mL of glucose-free medium to remove all 
metabolites that had been secreted into the medium. The cells were then used 
to inoculate the shake flasks containing 30 mL M9 medium containing [1,2-
13C2]glucose. Harvesting was performed in strictly exponential growth. For the 
control experiment, cells were also washed with M9 medium containing 3 g/L 
[1,2-13C2]glucose. The cells were then used to inoculate the 250 mL shake 
flasks containing 30 mL M9 medium with [1,2-13C2]glucose. Harvesting and 
extractions as well as quantification were also done as described above. 
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Table 13: SRM Transitions for selected metabolites used in flux analysis. Transitions indicated in bold were used as signature isotopomers 
  unlabeled +1 +2 +3 +4 +5 +6 
Analyte Product ion Q1 Q3 Q1 Q3 Q1 Q3 Q1 Q3 Q1 Q3 Q1 Q3 Q1 Q3 
Glutamate -CO2 146 102 147 102/103 148 103/104 149 104/105 150 105/106 151 106   
Aspartate -CO2 132 88 133 88/89 134 89/90 135 90/91 136 91     
Lactate -CO2 89 43 90 43/44 91 44/45 92 45       
G6P [H2PO4]- 259 97 260 97 261 97 262 97 263 97 264 97 265 97 
F6P [H2PO4]- 259 97 260 97 261 97 262 97 263 97 264 97 265 97 
Glycerol-1P [PO3]- 171 79 172 79 173 79 174 79       
Glycerol-2P [PO3]- 171 79 172 79 173 79 174 79       
Pyruvate -CO2 87 43 88 43/44 89 44/45 89 45       
Succinate -CO2 117 73 118 73/74 119 74/75 120 75/76 121 76     
Malate -H2O 133 115 134 116 135 117 136 118 137 119     
2-Ketoglutarate -CO2 145 101 146 101/102 147 102/103 148 103/104 149 104/105 150 105   
Fumarate -CO2 115 71 116 71/72 117 72/73 118 73/74 119 74     
P-Glycerate [H2PO4]- 185 97 186 97 187 97 188 97       
FBP [H2PO4]- 338 97 339 97 340 97 341 97 342 97 343 97 344 97 
cis-Aconitate -2 CO2 173 85 174 85/86 175 85/86/87 176 86/87/88 177 87/88/89 178 89 179 89 
DHAP [H2PO4]- 169 97 170 97 171 97 172 97       
Lactoylglutathione Glutathione 378 306 379 306 380 306         
Acetyl-CoA [PO3]- 808 79 809 79 810 79 811 79 812 79     
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11.2.3 Experimental details for cell harvesting and metabolite 
extraction 
Cell harvesting and extraction was done as described in Chapter 7, with the 
following modifications. After fast filtration, an aliquot of the filtered medium 
was taken for the analysis of extracellular metabolites. The extraction solution 
consisted of 80% (v/v) methanol in water at -20ºC, containing the extraction 
standards [2,3,3,3-2H4]lactate, [U-2H]succinate, [2,3,3-2H3]malate, [2,3,3,4,4-
2H5]glutamate, [U-13C]fumarate, [U-13C]pyruvate, [U-13C]glucose-1-phosphate 
and [U-13C, U-15N]AMP. Sample preparation for media samples was very 
simple, a 100 μL aliquot was mixed with internal standard and directly 
measured by LC-MS/MS. 
11.3 Results and Discussion 
11.3.1 13C-Label distribution in extracellular lactate 
For the measurement of lactate in cell medium, several milliliters of medium 
were collected after fast filtration of cells. An aliquot of 100 μL medium was 
mixed with internal standards and directly measured by LC-MS/MS. Lactate 
fragments under the chosen SRM parameters by loss of C1 as H2CO2 (Figure 
25).  
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Figure 25: Fragmentation and labelling pattern of lactic acid in MS/MS experiments. Bold red 
fonts indicate 13C labeled carbon atoms. 
This fact can be used to distinguish different labeling patterns derived from 
metabolization of labeled glucose via different pathways. If [1,2-13C2]glucose is 
metabolized by glycolysis, the label is redistributed to C2 and C3 of lactate. 
On the other hand, in the PPP, 1,3-13C2-lactate as well as well as 3-13C1-
lactate are produced (Figure 26). By comparing the excretion of the different 
isotopes, one can estimate the relative flux distributions of glucose between 
glycolysis and the PPP.  
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Figure 26: Metabolism of [1,2-13C2]glucose. Label distribution through important intermediates 
of glycolysis, PPP and MG-pathway is shown. 13C labelled atoms are indicated by a star (). 
In a proof-of-principle study, we compared the glucose metabolism of a 
double-deletion mutant of E. coli, which lacks the transhydrogenases UdhA 
and PntAB, with that of the corresponding wild type strain. The membrane-
bound proton-translocating transhydrogenase PntAB is a major source of 
NADPH in E. coli, that produces during aerobic batch growth 35–45% of the 
NADPH required for biosynthesis, whereas pentose phosphate pathway and 
isocitrate dehydrogenase contribute 35–45% and 20–25%, respectively.12 The 
soluble energy-independent transhydrogenase UdhA, in contrast, catalyzes 
the reoxidation of excess NADPH. Consequently, deletion of these two 
transhydrogenases will lead to a compensatory increase in the generation of 
anabolic reductant NADPH in the first reaction of the oxidative branch of the 
PPP, the dehydrogenation of G6P to 6-phosphoglucono-δ-lactone, and by 
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isocitrate dehydrogenase. The increased flux through the PPP will in turn 
result in a decreased glucose flux through glycolysis as already demonstrated 
by Sauer et al. (2004) employing metabolic flux ratio analysis by GC-MS. It 
was also demonstrated that metabolite levels for many compounds of the 
central carbon metabolism are significantly different in the mutant as 
compared to the wild type strain.137 In the present study, our aim was to 
evaluate the ability of the RR-IP-LC-MS/MS method to detect these changes 
in glycolytic fluxes based on the isotope distribution in extracellular lactic acid. 
To this end the two strains were grown on minimal medium containing 100% 
[1,2-13C2]glucose. In initial experiments it became obvious that the aliquot of 
the over-night culture used to inoculate the shake flasks contained a high 
amount of unlabeled lactate (data not shown). Since we were only interested 
in lactate excreted by the cells under our experimental conditions, we decided 
to wash the inoculum with fresh, glucose-free medium before use. We 
measured the supernatant after each washing step and found that all the 
extracellular lactate was removed after the third iteration.  
As described above, we used the ratio of 2,3-13C2-lactate in the wild type vs. 
the mutant strain to estimate the difference in flux through glycolysis. Pub-
lished data show that the flux through glycolysis was 68% of total glucose flux 
in the wild type strain,138 while it was estimated at 52% in the PntAB-UdhA 
mutant.12 This amounts to a ratio of 0.76 (PU vs. wt). Our measurement 
yielded a ratio of 0.71. For the flux through the PPP, values of 32% (wt) and 
47% (PU) had been reported.12, 138 The theoretical ratio of 1.49 (PU vs. wt) 
again corresponds well with our measured value of 1.32 (Figure 27). Thus, our 
method is clearly able to give a first estimate on alterations in flux distributions, 
without the need for elaborate modeling and computation. However, it is not 
feasible to calculate absolute flux values, at least not without prior knowledge 
of absolute flux values in a reference strain, in part because lactate from gly-
colysis is found in much higher amounts than lactate from PPP. 
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Figure 27: Flux distribution in the wild type strain as compared to the PntAB-UdhA mutant. 
Bold entries in the solid boxes denote our estimates in comparison to the estimates reported 
by 12, 138, respectively, which are listed in the dashed boxes. 
11.3.2 The methylglyoxal pathway 
As shown in Figure 26, in the course of glycolysis FBP is split in a reversible 
enzymatic reaction catalyzed by FBP-aldolase into DHAP and glyceraldehyde-
3-P. Therefore, one would expect a ratio of unlabeled vs. +2-labelled lactate of 
1 (i.e. 50% unlabelled vs. 50% labeled). After we had started washing the 
inoculum to remove any extracellular metabolites, especially unlabeled lactate, 
we consistently found an excess of 2,3-13C2-lactate as compared to unlabeled 
lactate and this difference was always higher for the wild type (~0.8) as for the 
mutant (~0.9). The same observation was made for several intracellular 
metabolites such as pyruvate or DHAP, yet not for 3-phosphoglycerate (Figure 
28).  
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Figure 28: Ratios of the unlabelled vs. the +2-labelled isotopomer for different compounds. 
The upper entry denotes the ratio for the wild type strain, while the lower entry indicates the 
value for the PntAB-UdhA mutant. 
After excluding measurement errors and ensuring the purity of the labeled glu-
cose, we investigated the only step during glycolysis, where the labeled half of 
the [1,2-13C2]glucose molecule reacts differently than the lower, unlabeled half, 
i.e. the conversion of FBP to DHAP and GAP. The upper three carbon atoms, 
C1 – C3, of FBP initially end up in DHAP, while C4 – C6 end up in GAP. The 
enzyme triosephosphate isomerase, Tpi, catalyzes the isomerization of these 
two compounds. In Δtpi strains, the accumulating DHAP is processed by a 
different set of reactions, the methylglyoxal (MG) pathway (Figure 26).138 
DHAP is converted to MG by methylglyoxal synthase. MG is toxic for E. coli 
cells and, therefore, is removed by conversion to D-lactate via lactoyl-
glutathione or L-lactate, which requires NADPH.139  
However, MG pathway activity has been described in other E. coli strains; it 
was identified as a source of chiral contamination in lactate and alanine fer-
mentation.139, 140 The pathway was also active after a glucose pulse, 
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presumably to replenish the intracellular inorganic phosphate pool and to pre-
vent the accumulation of phosphorylated intermediates of glycolysis.141 We 
propose that MG pathway activity has been responsible for the imbalance in 
the ratio of unlabeled to labeled lactate, by directly shuttling DHAP towards 
lactate and pyruvate, respectively. This would explain the observed results for 
lactate, pyruvate and DHAP and the different result for phosphoglycerate. In 
order to test this hypothesis we measured a specific intermediate of the MG 
pathway, lactoylglutathione (LG). The specific SRM transition 378 Æ 306 (loss 
of the lactate moiety) was chosen for the measurement of intracellular LG. A 
clear LG peak was seen in all the samples derived from the washed inoculum, 
while no LG was seen in control samples grown on LB medium (Figure 29). 
Also, about 2.5 times more LG was detected in the wild type samples as 
compared to the mutant and the ratio of LG vs. LG+2 was 95% for the mutant 
and 89% for the wild type strain. These findings strongly support the 
hypothesis that the MG pathway was upregulated under the applied 
conditions. 
Figure 29: Measurement of LG in different samples. A) LG standard in water, 10 μM. B) E. 
coli sample grown on M9 medium, washed inoculum. C) E. coli sample grown on LB medium. 
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As mentioned above, the activation of the MG pathway is described under 
conditions of glucose limitation and subsequent glucose pulse.141 We there-
fore wanted to evaluate the influence of washing the inoculum on the 
observed flux distribution. To this end we repeated the experiment as 
described above, with the exception of washing the inoculum with M9 medium 
supplemented with 3 g/L [1,2-13C2]glucose. This was done in order to maintain 
the extracellular glucose level, while at the same time preventing the formation 
of unlabelled glucose metabolites. Under these conditions, we found ratios 
close to 1 for the unlabelled vs. the +2-labelled isotopomers of the metabolites 
involved in the lower part of glycolysis (Figure 30). Thus, the initial washing 
procedure is substantially responsible for the observed flux through the MG 
pathway. In order to definitely exclude any effect of the MG pathway on the 
label distribution towards lactate, an MG pathway deletion mutant would have 
to be analyzed. 
 
Figure 30: Ratios of the unlabelled vs. the +2-labelled isotopomer for different compounds. 
The upper entry denotes the ratio (average of the two strains) upon glucose deprivation during 
sample preparation while the lower entry denotes the ratio upon addition of labelled glucose 
during the washing step. 
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11.3.3 Information derived from other metabolites – the 
tricarboxylic acid cycle (TCA) 
The findings for the different isotopomers of lactate described in the previous 
sections are very well suited for the rapid assessment of perturbations in the 
upper part of the central carbon metabolism. However, additional information 
on cellular processes can be gained from the analysis of other metabolites 
and their corresponding isotopes. Nevertheless, since most metabolites are 
not excreted into the cell medium in amounts similar to lactic acid, they are 
preferably analyzed in cell extracts. We established SRM transitions for all 
possible isotopomers of the most informative intermediates of the central 
carbon metabolism that were amenable to IP-LC-MS/MS analysis (Table 13). 
These measurements yielded a substantial amount of data, in part due to the 
fact that different possibilities exist for loss or retention of the label during 
fragmentation in MS/MS mode. Also, the multitude of analyzed SRMs 
necessitated the subdivision of the MS run into four periods. However, this fact 
could also be used to gain additional information on the localization of labeled 
13C atoms in the molecule, which was useful in the correlation of isotope 
labeling patterns with their corresponding metabolic pathways. 
During the analysis of isotopomer distributions, remarkable differences for 
different labeling states in the wild type vs. the PntAB-UdhA mutant strain be-
came apparent. As depicted in Figure 31, significant differences, as deter-
mined by a Student’s t-test with P<0.05, were for example seen for the +3 and 
the fully labeled states in the two strains. While the +3-labeling state was 
always higher in the mutant strain, the uniformly labeled state was found to a 
higher degree in the wild type strain. 
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Figure 31: Ratio of two different labelling states (+3 vs. fully labeled) for different TCA 
intermediates in the wild type vs. the PntAB-UdhA mutant strain and ratios of absolute 
metabolites levels (Qabs) in the wild type vs. the mutant strain. Values marked in bold indicate 
significant differences between the different labelling states of the two strains (Student’s t-test, 
p<0.05). 
We then investigated in more detail the 13C-label distribution in the TCA cycle. 
In the first pass through the TCA cycle, both 13C-labeled atoms from acetyl-
CoA are retained in the metabolic intermediates (Figure 32 A/I). Succinate is a 
symmetric molecule; therefore, the labeling pattern of the subsequent metabo-
lites is not fixed. However, for the conclusions drawn here, it does not make 
any difference, if these metabolites are labeled at positions 1 and 2 or at posi-
tions 3 and 4.  
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Figure 32: Distribution of 13C-labeling in the first (I) and the second (II) pass through the tricar-
boxylic acid cycle (A) and the glyoxylate pathway (B). Solid black stars ( ) denote labelled 
13C atoms entering the cycle. Empty stars ( ) denote labelled atoms in that had entered from 
the previous pass. Succinate is a symmetric molecule and, therefore, it is impossible to dis-
cern whether positions 1 and 2 or 3 and 4 are isotope labeled. For clarity’s sake, only one of 
the two possibilities is denoted. In both cases one labelled 13CO2 molecule would leave in the 
next turn of the TCA. 
A 
B 
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This is due to the fact that in the second pass through the TCA (Figure 32 
A/II), one of the two labeled 13C atoms is lost as 13CO2, leaving a molecule 
with a uneven number of labeled carbons. The higher number of +3 labeled 
intermediates in the mutant strain might thus be explained by the higher flux 
through the TCA, as was already hypothesized previously.83 
However, this did not explain the opposite trend for fully labeled intermediates. 
Therefore, we investigated alterations in the TCA cycle and found several 
descriptions on the activity of the glyoxylate shunt as a bypass flux of the 
TCA.138 While this pathway is mainly activated upon growth on acetate 142, it 
was also described under conditions of glucose limitation 143, 144 and as 
modulated by the NADPH/NADP ratio.145 Therefore, we hypothesized that the 
glyoxylate shunt is activated upon glucose limitation during the initial washing 
step, and that this activation is substantially larger in the wild type strain than 
in the mutant. This could be due to the fact that the PntAB-UdhA mutant has 
to rely on the activity of the enzyme isocitrate dehydrogenase in order to 
produce NADPH, while the wild type strain uses the bypass to keep up the 
production of amino acid precursors while at the same time balancing its 
NADPH/NADP ratio. The distribution of 13C-labeled atoms through the 
glyoxylate bypass is depicted in Figure 32/B. It is evident, that the activity of 
this metabolic pathway would lead to an increased production of fully labeled 
intermediates, as observed predominantly in the wild type strain (Figure 31). 
We tried to confirm this hypothesis by measuring intracellular levels of 
glyoxylate. However, ionization efficiency of the main product was insufficient 
for detection of glyoxylate in our E. coli samples. 
As noted above, the measurement of all possible isotopomers of even a 
selection of analytes leads to a high number of SRM transitions. Since dwell 
times have to be set to at least 30 ms and a sufficient number of data points 
have to be recorded for each peak for reliable quantification, this would 
necessitate multiple analyses for each sample. To circumvent this severe 
drawback towards high-throughput analysis, we established specific SRMs 
from the observations described above without limiting the drawing of 
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meaningful conclusions on carbon fluxes from the data. This signature SRMs, 
as depicted in Table 13 in bold, can be easily measured in a single run, which 
is subdivided into four periods, with a maximum of 17 SRMs per period, 
corresponding to a cycle time of ~0.5 s. 
We also measured the absolute intracellular levels of several TCA cycle inter-
mediates and the amino acids aspartate and glutamate by summing all 
detected isotopomers for each compound. The results obtained correlated well 
with our previously published CE-TOF-MS data; for instance, the levels of 
fumarate measured by LC-MS/MS were 0.27 and 0.54 nmol per mg cell dry 
weight (cdw) for wild type and mutant, respectively, while the corresponding 
CE-TOF-MS values were 0.35 and 0.54.18 Generally, higher amounts of TCA 
cycle intermediates were found for the mutant strain as compared to the wild 
type (Figure 31). 
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12  Conclusion and Outlook 
To date the most promising approach to tackle the enormous complexity of the 
metabolome is the combination of several different methods for metabolome 
analysis. In this thesis I demonstrated the development, validation and appli-
cation of two different methodologies. Each of them is highly suitable to certain 
biological problems but can also be used as more universal analytical tools. 
The strength of the CE-TOF-MS based method is its ability for high-confidence 
identification of additional metabolites of interest, while still providing reliable 
quantitative data. The RR-IP-LC-MS/MS method yields accurate quantitative 
information on selected metabolites over a wide dynamic range and is very 
well suited for the highly sensitive detection of minor components of a complex 
mixture. Nevertheless, it can also be used for initial screening approaches that 
can later be transferred to a high-resolution MS system for identification.  
The methods were applied to various biological problems, with a high empha-
sis on thorough validation of the complete sample preparation and measure-
ment process. This was achieved by optimizing protocols and by the introduc-
tion of several internal standards as well as different quality control measures. 
We could demonstrate that our approaches were able to reliably answer a 
variety of biological questions in different cellular systems. 
However, several points remain to be addressed: 
- The panel of metabolites that are absolutely quantified by both methods 
has to be extended, as well as the number of confirmed metabolite hits 
derived from TOF-MS based analysis 
- Along the same line the panel of internal standard compounds should be 
extended. A promising approach in this regard is the use of uniformly 13C, 
15N labeled biomass, which theoretically would provide standards for all the 
metabolites contained in the organism at much lower overall costs. The 
suitability of this procedure is now under investigation. 
 106
- Regarding the data on flux analysis in E. coli, additional strains with disrup-
tions in the central carbon metabolism have to be analyzed in order to 
evaluate the ability of the described method to detect these alterations in a 
reliable fashion. Also, the kinetic of label distribution throughout the cellular 
network is of high interest, as well as its time-resolved behavior to pertur-
bations. In order to cope with the large number of samples, analysis time 
will have to be reduced further by using even smaller stationary phase 
particles and higher column pressures. 
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14 Appendix 
Table S1. List of average CE migration times in ascending order, observed masses, database hits, peak area ratios of wt over PntAB-UdhA 
under three different growth conditions, and ability of each of the three analytical methods employed to detect, respectively quantitate a given 
E. coli metabolite. 
Average 
MTa) [s] 
Observed 
mass Database ID 
LB 
(Stat) 
M9 
(Log) 
M9 
(Stat) Comment
b) CE-TOF-MSc) 
GC-
(AA)-
MSc) 
GC-
MSc) 
466.1 129.0196 Itaconate 0.02* n.d. 0.4* ; #   
466.8 115.0045 Fumarate 0.15* 0.46* 0.47* ; #  x 
468.1 87.00676 Pyruvate 0.31* n.d. 0.27 ; #  x 
468.7 306.9631  0.12* 0.07* 0.23* C5H9O11P2 / C6H5N4O7P2 #   
468.9 111.0089 Furoic acid 0.05* 7.8* 0.13* Formula ok! #   
469.4 191.0207 Citrate 0.005* 0.01* 0.08* ; #  x 
467.8 192.0255  0.05* n.d. n.d. Isotope of Citrate #   
469.5 270.0561  0.34* n.d. 0.26* C6H12N3O9 #   
472.4 246.9436 Cyclic 2,3-bisphospho-glycerate 0.1* 0.07* 0.26* Formula ok #   
472.8 149.01 Tartaric acid 0.64 n.d. n.d. ; #   
472.9 193.0265 Glucuronate 0.04* 0.15* 0.12* ; #   
473.8 196.056 3-hydroxytyrosine n.d. n.d. 0.98 Isotope of glucuronate #   
474.4 136.0349 Malate-d3 (IS) 0.81 0.78 1 ; #   
475.1 135.0282 Hypoxanthine 0.93 1.29 0.95 Isotope of Malate-d3 #   
475.3 133.0162 Malate 0.17* 0.27* 0.38* ; #  x 
476.4 134.0213 Homocysteine 0.08* 0.63 0.47* Isotope of Malate #   
474.7 137.0374 Urocanate, 0.81 n.d. 0.97 Formula ok! #   
473.8 138.0391  0.91 1.01 0.98 Isotope of urocanate #   
474.7 405.0313  0.03* 0.15* 0.05* C13H14N2O11P #   
475.3 173.009 cis-Aconitate 0.01* 0.09* 0.17* ; #  x 
476.2 145.0131 alpha-Ketoglutarate 0.96 0.58 1.08 ; #  x 
476.5 121.0453 Succinate-d4 (IS) 0.96 0.9 1.06 ; #   
476.7 123.0496 4-Hydroxybenzyl alcohol 1.04 1.09 0.84 Succ-d4-13C2 #   
476.7 122.0489  0.96 1.08 1.1 Succ-d4-13C #   
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477.4 120.0393  0.93 1.03 0.98 Succ-d3 #   
477.7 117.0197 Succinate 0.71* 0.65* 0.54* ; #  x 
477.6 118.0225 3-Nitropropanoate n.d. n.d. 0.83 Isotope of succinate #   
479.4 281.062  0.47* 0.92 n.d. C8H13N2O9 #   
479.7 265.0784 p-Aminobenzoyl glutamate 1 n.d. 0.96 Formula ok! #  x 
493.3 147.0314 2-Hydroxyglutarate, citramalate 1.06 0.73 2.06* Formula ok! #   
494.7 246.0617 N2-succinylglutamate 0.58* 0.42* 0.3* Formula ok! #   
495.4 247.0647 5-Hydroxyindoleacetylglycine n.d. n.d. 0.27* Isotope of N2-succinyl glutamate #   
496.0 205.0347 2-Methylcitrate, methylisocitrate 0.07* 0.03* 0.26* Formula ok! #   
496.6 184.9863 Phosphoglycerate 0.48* 1.87* 0.72* ; #  x 
497.0 166.9729 Phosphoenolpyruvate 0.58* 0.88 0.72 ; #   
499.3 131.0379 4-hydroxy-2-ketovalerate, 2-aceto-lactate 0.76 n.d. n.d. Formula ok! #   
499.4 260.0823  1.32 0.28* 0.15* C9H15N3O4P #   
508.0 105.0201 Glycerate 0.1* 1.34 0.81 Formula ok! #  x 
512.5 119.0364 Dihydroxybutyric acid, Dihydroxyisobutyric acid 1.06 0.79 0.98 Formula ok! #   
517.6 175.037 N-carbamoyl-aspartate, 0.21* 132.05* 2.36* Formula ok! #   
518.7 176.0384 N-Formyl-L-methionine n.d. 22.72*  Isotope of N-Carbamoyl aspartate #   
520.2 174.0407 N-Acetylaspartate , 2-Amino-3-oxoadipate 0.4* 10.55* 2.55* Formula ok! #   
530.8 181.0508 3-(2,3-dihydroxyphenyl)propionate 2.93* n.d. 2.61* Formula ok! #   
533.7 188.059 N-acetyl-glutamate 7.96* 1.12 n.d. Formula ok! #   
534.7 159.0712 Dimethylglutarate 1.26   Formula ok! #   
543.5 168.9915 Glyceraldehyde-3-P, dihydroxy-acetone-P 0.35* n.d. 0.65 Formula ok! #   
552.2 171.0088 Glycerol-phosphate 0.61* 7.66* 2.28* ; #  x 
556.1 363.0555  0.93 1.02 0.94  #   
554.9 365.0531 Phosphoribosyl-formamido-carboxamide 1.22 0.76 1.31 Isotope of 363.0555 #   
557.8 364.0588  0.89 0.97 n.d. Isotope of 363.0555 #   
556.1 301.0558 PIPES (IS) 1 1.04 0.96 ; #   
555.7 150.0222  0.97 0.98 0.98 PIPES 2- #   
555.3 150.5244  1.05 0.97 1 Isotope of PIPES 2- #   
556.7 304.0543  0.81 0.76 n.d. Isotope of PIPES #   
557.9 302.058  0.96 1.21 0.96 Isotope of PIPES #   
557.0 303.053  0.94 1.01 0.94 Isotope of PIPES #   
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556.8 257.0799 3-Methyluridin , ribosylimidazoleacetic acid 1.81* 0.51* 0.85 Formula ok! #   
557.3 305.0484  2.17* n.d. n.d. C7H9N6O8 #   
557.4 91.03743 Glycerol 0.47* 1 0.97 Formula ok! #   
557.4 412.8818  n.d. 3.83* 7.63* C9H4O13P3 #  x 
559.0 110.9865 Hydroxymethylphosphonate n.d. 1.48 1.13 Formula ok! #   
568.8 229.0125 Pentose-P 0.54 n.d. 0.73 ; #d)   
569.4 255.2328 Palmitate 0.74 1.18 n.d. Formula ok! #  x 
570.3 92.03308 Lactate-13C3 (IS) 1.04 1 1 ; #   
570.9 89.02238 Lactate 1.27 4.07* 1.31* ; #  x 
583.4 403.000 UDP 0.29* n.d. 1.48 ; #   
586.7 402.0107 CDP 0.28 1.23 1.95* ; #   
587.6 115.0423 2-Keto-isovalerate 1.02 1.02 1.2 Formula ok! #   
588.0 579.0282 UDP-D-glucuronate 0.56 0.97 0.91 ; #   
594.1 390.9012  0* 6.82* 23.87* C7H6O13P3 #   
594.8 87.0424 2-Methylpropanoate, butyrate, acetoin 2.14 n.d. 1.29 Formula ok! #   
595.3 122.0303 Picolinate, nicotinic acid 1.98 1.46 0.81 Formula ok! #   
601.4 112.9865 Acetylenedicarboxylate, n.d. n.d. 0.08* Formula ok! #   
602.7 259.0221 Hexose-P 0.5* 0.35* 1.37* ; #d)  x 
600.4 261.0366 Mannitol-1-P, galactitol-1-P, D-sorbitol-6-P 0.34* 0.71 1.38 Isotope of Hex-P #   
603.4 260.027 O-phospho-L-tyrosine 0.36* 0.37*  Isotope of Hex-P #   
602.8 182.0154 L-homocysteic acid 4.98* n.d. n.d. Formula ok! #   
603.2 155.005 Orotate 0.26* 11.65* 1.03 ; #  x 
603.7 156.0096  n.d. 9.05* n.d. Isotope of Orotate #   
603.7 176.9352 Diphosphate, n.d. 4.27* 3.33 Formula ok! #   
604.6 129.0566 2-Keto-4-methyl-pentanoate, 2-keto-3-methyl-valerate 0.87 0.74* 0.56* Formula ok! #   
605.1 678.0978 UDP-N-acetylmuramate 0.41* 0.55* 0.54* Formula ok! #   
605.4 323.0324 UMP 0.36* 1.4 0.98 ; #   
605.9 426.0241 ADP 0.81 1 1.96* ; #   
608.8 287.0541 Orotidine 8.53* n.d. 1.29 Formula ok! #   
610.2 289.0331 Sedoheptulose-7-P 0.57* 0.99 1.05 Formula ok! #   
610.9 131.0364 Glutarate 1.25 0.65* 2.19* ; #   
611.1 128.0358 5-Oxo-D-proline 5.95* 1.85* 2.15* Formula ok! #   
612.4 164.0364 Methionine sulfoxide 2.99 n.d. n.d. Formula ok! #   
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612.5 322.0466 CMP 0.49* 0.67 1.03 ; #   
613.2 321.0493 dTMP 0.26* 0.77 0.69 ; #   
616.1 132.032 Aspartate 2.04* 0.83 1.39* ; # x  
616.1 138.9728 Phosphonoacetate, acetylphosphate n.d. 1.97 1.15 Formula ok! #   
619.8 175.0621 Isopropylmalate n.d. n.d. 24.67 Formula ok! #   
621.8 346.0586 AMP 0.46* 1.53 1.16 ; #  x 
629.6 236.0965  3.01* n.d. 0.77 C12H14NO4 #   
632.3 115.077 Caproic acid 1.39* 1.49* 1.1 ; #  x 
633.7 133.0454 2,3-Dihydroxy-isovalerate,deoxyribose, 1-deoxy-xylulose 3.43* n.d. 1.43 Formula ok! #   
633.8 228.0544 5-(L-Alanin-3-yl)-2-hydroxy-cis,cis-muconate 6-semialdehyde 3.35* n.d. 2.66* Formula ok #   
634.9 102.0542 Aminobutyrate, 2.75* 1.45* 2.04* Formula ok! #   
635.1 258.0401 Glucosamine-6-phosphate 0.29* 1.65 1.63* ; #   
635.6 320.1146 Tripeptide 1.42* 1.17 1.37* Formula ok! #   
635.7 173.0608 N-formimino-glutamate, 0.37* 1.06 0.55* Formula ok! #   
636.1 298.134  2.38* 1.14 n.d. C14H20NO6 #   
635.9 151.0779 Glutamate-d5 (IS) 0.91 1.01 0.97 ; #   
636.3 146.0475 Glutamate 2.78* 2.11* 2.33* ; # x  
635.4 147.0538 Dihydrocoumarin 2.7* 1.32 2.16* Isotope of Glutamate #   
637.0 148.0501 Methionine, penicillamine 7.1* 1.1 2.16* Isotope of Glutamate #   
636.3 168.0291 2,3-Dihydrodipicolinate, 1.94* 1.3 1.57* Formula ok! #   
637.8 121.0312 Benzoate 2.74* 2.17* 1 ; #  x 
638.4 315.0839  4.5* 1.97* 2.68* C12H15N2O8 #   
638.7 316.0879 Desmethylnizatidine 9.95* n.d. 2.74* Isotope of 315.0839 #   
636.3 595.6624  0.69 1.48 1.26 1193.32 2- #   
634.6 596.1637  0.6* 1.25 1.27 Isotope of 595.67 #   
640.5 596.6722  0.63* 1.68 1.63 Isotope of 595.67 #   
640.5 597.1724  0.87 n.d. n.d. Isotope of 595.67 #   
641.2 349.0273 N-Phospho-D-lombricine 15.36* n.d. 2.69* Formula ok! #   
643.2 742.0748 NADP/NADPH 1.52 1.62 5.01* ; #   
645.3 129.0915 Heptanoic acid 1.51 1.51* n.d. ; #   
645.3 154.0123  1.77* 0.79 1.13 C6H4NO4 #   
646.9 154.0895  1.13 1.02 0.96 Cinnamic acid–d7 (IS) #   
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644.1 155.0939  1.06 0.94 0.96 Isotope of Cin-d7 #   
642.0 156.096  1.03 0.99 0.97 Isotope of Cin-d7 #   
648.4 282.022  1.08 1.53* 2.29* C6H8N3O10 #   
652.1 565.049 UDP-glucose 0.84* 1.17 2.43* ; #   
656.6 375.1053  0.92 1.35* 1 C13H20N4O7P #   
657.9 547.0748 dTDP-alpha-L-rhamnose 1.58* 1.32 1.35* Formula ok! #   
657.7 548.0807  2.73* 1.83* 1.35 Isotope of dTDP-rhamnose #   
660.1 143.1081 Octanoate 1.62* 0.83 1.03 ; #  x 
661.4 611.1457 Glutathione disulfide (GSSG) 1.3 1.14 1.11 Formula ok! #   
660.5 612.1484  1.27 1.54 1.08 Isotope of GSSG #   
661.2 613.1473  1.54 2.13 n.d. Isotope of GSSG #   
662.0 606.0758 UDP-N-acetyl-galactosamine, UDP-N-acetyl-glucosamine, UDP-N-acetyl-mannosamine 0.46* 0.95 0.88 Formula ok! #   
665.0 302.5349  0.24* 0.93 0.76* z=2 of 606.0758 #   
665.1 607.0849  0.33* n.d. n.d. Isotope of 606.0758 #   
662.8 101.0592 Valeric acid n.d. 1.59 1.22 ; #  x 
663.5 333.0295  2.06* 1.96* 0.93 C12H15O7P2 #   
664.7 334.0289 Nicotinic acid mononucleotide 2.7* 1.84 0.64 Isotope of 333.0295 #   
665.0 145.0609 Glutamine n.d. 0.35* 1.7* ; x #  
672.0 157.1244 Nonanoic acid 0.99 1.28 1.05 ; #   
681.7 241.0136 Inositol cyclic phosphate 0.05* n.d. 1.09 Formula ok! #   
682.2 225.0902 Porphobilinogen 2.32 n.d. n.d. Formula ok! #   
682.8 171.1377 Capric acid 1.39 1.12 0.59 ; #  x 
684.9 328.0623  1.69* 1.29 1.3  C13H15NO7P #   
686.1 613.1512  3.01* 2.41* 1.98* C21H35N4O13P2 / C22H34N2O16P 
#   
686.2 306.075 Glutathione 1.89* 1.64 1.44* ; #   
686.4 307.0819  1.39 1.47 1.28 Isotope of glutathione #   
686.5 179.0545 Glucose 0.86* n.d. 0.36* ; x  # 
687.2 334.1247 N4-(b-N-Acetyl-glucosaminyl)-asparagine n.d. 0.53* 0.58* Formula ok! #   
698.1 215.0492 Bisnorbiotin n.d. 1.02 0.95 Formula ok! #   
704.4 189.0781 3-Hydroxysuberic acid n.d. n.d. 6.59* Formula ok #   
705.3 218.1047 Pantothenate 1.47* 0.68 1.18 ; #  x 
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706.0 101.0222 Succinate semialdehyde, acetoacetate, 2-oxobutanoate n.d. n.d. 2.09 Formula ok! #   
706.8 332.1467 Tripeptide n.d. 0.58* 0.75* Formula ok! #   
709.9 274.1077 Tripeptide 1.43* 0.85 n.d. Formula ok! #   
712.1 182.0437 Methyl(2-furoylamino)acetic acid n.d. 0.24* 0.13* Formula ok! #   
717.4 253.0816 Hydroxyfelbamate 1.82* n.d. 0.29* Formula ok #   
717.6 288.1225 Tripeptide 1.63* 1.1 n.d. Formula ok! #   
719.8 289.1218 L-Arginino-succinate, 0.88 1.38 0.75 Isotope of Tripeptide (288.12) #   
719.3 231.098 N2-Succinyl-ornithine 1.4* 0.76 0.45* Formula ok! #   
721.5 232.105  1.3 n.d. 0.33* Isotope of N2-succinyl-ornithine #   
719.8 275.0936 Dipeptide (Glu-Glu) 0.94 1.37* 1.06 Formula ok! #   
720.6 88.03704 Alanine 0.51* n.d. 1.9* ; x # x 
729.9 245.1176 Dipeptide 1.78* 0.26* 0.15* Formula ok! #   
728.7 246.1167  n.d. 0.4* 0.13* Isotope of 245.11 #   
736.5 273.1213 N2-Succinyl-arginine, 2.02* 0.56 0.95 Formula ok! #   
734.3 274.1271  1.52 n.d. n.d. Isotope of N2-succinyl-arginine #   
740.4 275.1282  5.02* n.d. n.d. Isotope of N2-succinyl-arginine #   
765.0 328.0532 cyclic-AMP n.d. 2.69* n.d. ; #   
773.0 159.0788 Alanyl-alanine 1.64 n.d. n.d. Formula ok! #   
777.1 205.0831 Dipeptide (Thr-Ser) n.d. 0.67 0.74 Formula ok! #   
799.1 421.0746 Lactose 6-P, trehalose 6-P, maltose 6'-P, sucrose 6-P n.d. 0.08* n.d. Formula ok! #   
800.2 662.1055 NAD/NADH 0.83 0.65* 1.08 ; #   
807.5 663.1085 NAAD 1.13 0.79 1.05 Isotope of NADH #   
809.6 203.1036 Dipeptide (Val-Ser) n.d. 0.7 0.72 Formula ok! #   
834.9 217.1188 Dipeptide , N2-(D-1-Carboxyethyl)-lysine n.d. 0.45* 0.95 Formula ok! #   
851.1 185.0793  0.92 0.47* 0.96 C8H13N2OS #   
854.8 116.0746 Betaine 0.07 n.d. n.d. Formula ok! #   
855.1 130.0886 Leucine 1.5* 1.42 0.17* ; xe) # x 
855.1 130.0886 Iso-leucine 1.67* 1.26 wt only* ; x
e) # x 
881.6 103.0399 3-Hydroxy-isobutyrate 1.01 n.d. n.d. Formula ok! #   
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876.4 104.0431 Serine 0.99 n.d. n.d. Isotope of Hydroxy-isobutyrate #   
882.8 105.0415 Benzaldehyde 0.99 n.d. n.d. Isotope of Hydroxy-isobutyrate #   
881.6 304.1511 (6S)-Hydroxyhyoscyamine n.d. 0.48* 0.64* Formula ok! #   
885.7 319.127  n.d. 0.4* 0.35* C11H19N4O7 #   
1060.9 242.0789 Cytidine n.d. 5.45* n.d. ; #   
1061.4 135.0314 Hypoxanthine n.d. n.d. 0.46* ; #   
1088.1 243.0618 Uridine 2.07 9.61* 0.58* ; #   
1099.5 266.0889 Adenosine n.d. 7.94* 0.81 ; #   
1113.5 266.0763 S-Ribosyl-L-homocysteine n.d. n.d. 2.11 Formula ok #   
1115.1 326.1116 Tripeptide n.d. 11.53* 0.46* Formula ok! #   
1145.5 134.048 Adenine n.d. 1.64 0.46* ; #   
1146.4 253.2166 Palmitoleic acid n.d. 2.47* 10.22* Formula ok! #   
1160.9 164.0709 Phenylalanine 1.34 1.36 0.49* ; x #  
1163.1 155.0004 2,5-Furandicarboxylic acid n.d. 3.22 0.81 Formula ok #   
1186.6 145.0977 Lysine 1.22* 1.01 0.29* ; x #  
1190.1 154.0623 Histidine 1.12 0.67* n.d. ; x #  
1192.6 111.0187 Uracil n.d. n.d. 0.49* ; #   
1194.7 178.0715 Glucosamine n.d. 0.45* 0.58 Formula ok! #   
1206.5 118.0478 Threonine n.d. 0.9 2.97* ; x #  
1207.8 167.0644 5-(3-Methyltriazen-1-yl)imidazole-4-carboxamide n.d. 1.21 0.82 Formula ok! #   
1208.2 121.0377 Nicotinamide n.d. 0.63 0.97 ; #  x 
1211.4 176.0921  n.d. 0.49* 0.68 C8H10N5 #   
1223.9 135.0645 5,6,7,8-Tetrahydropteridine n.d. n.d. 1.22 Formula ok! #   
1231.4 114.0567 Proline 0.16* 0.82 1.49* ; x #  
1234.9 341.1123 Sucrose 1.82* 0* 0* ; x f)  # 
1234.9 341.1123 Maltose PU only* 0* 0* ; x
 f)  # 
1237.5 116.0724 Valine 1.46* 1.33 1.78 ; x # x 
1237.5 173.1055 Arginine n.d. 1.58 1.34 ; #   
1244.6 123.0484 4-Hydroxybenzyl alcohol n.d. n.d. 1.01 ; #   
1248.2 435.2508 1-oleyl-2-lyso-phosphatidate n.d. n.d. 1.17 Formula ok! #   
1255.6 286.0412 Indole-3-glycerol-phosphate n.d. 1.03 0.94 Formula ok #   
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1318.5 405.2667 3,12-dihydroxy-7-oxo-5-beta-cholanate n.d. n.d. 0.87 Formula ok #   
1323.4 89.01938 Glyceraldehyde, dihydroxy-acetone n.d. n.d. 1.18 Formula ok! #   
1332.5 227.2012 Myristic acid n.d. 2.05 1.01 Formula ok! #  x 
1339.0 160.0636 Aminoadipic acid 4.9* 0.12* 0.09* ; x #  
1347.9 181.0088 1,3-Glyceryl dinitrate n.d. 0.97 1.28 Formula ok #   
1354.1 151.0608 Arabitol, ribitol 1.21 0.97 1.07 Formula ok! #   
* Significant difference between strains (p<0.05 in Student’s t-test) 
a) MT: corrected migration time in seconds 
b) ; - Consistent with commercial standard: Formula ok – generated formula consistent with database hit 
c) # - Method that yielded the quantitative data; x – alternative methods confirming metabolite identity 
d) Not resolved in MZMine 
e Leucine and iso-leucine migrated as a single peak in CE 
f) Maltose and sucrose migrated as a single peak in CE 
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17 Summary 
The combination of several different approaches is required for the 
comprehensive analysis of all the small molecules in a biological system, 
termed metabolomics. Here, we present two different strategies towards this 
final goal. A capillary electrophoresis - mass spectrometry method was 
developed and validated for the quantitative analysis of negatively charged 
metabolites by making use of the high mass accuracy and the quantitation 
capabilities of a time-of-flight mass analyzer in combination with automated 
feature extraction and database search. The method was used to elucidate 
metabolic changes in the Escherichia coli deletion mutant UdhA-PntAB that 
lacks nicotinamide nucleotide transhydrogenase function, under both 
stationary and exponential growth conditions. Concomitant analyses with two 
different gas chromatography-mass spectrometry methods allowed not only 
cross-validation of the quantitative results obtained by the various methods, 
but also led to a more comprehensive coverage of the E. coli metabolome. 
In the second approach we introduced rapid resolution ion pair-liquid 
chromatography - tandem mass spectrometry for the analysis of the 
isotopomer distribution in intermediates of the upper and the lower part of the 
central carbon metabolism, including glycolysis, PPP, TCA, and related 
pathways, in cells grown in culture media supplemented with 1,2-13C2-glucose. 
Additionally, reliable quantification of metabolites was achieved by the use of 
stable-isotope labeled internal standards. The applicability of the method was 
tested by comparing isotopomer distributions in central carbon intermediates 
in the two Escherichia coli strains described above. We observed in the 
mutant strain the expected increase in carbon flux through the oxidative PPP 
in concordance with published gas chromatography – mass spectrometry data 
on the mass isotope distribution in proteinogenic amino acids. We also 
observed in the mutant a relative increase in carbon flux through the NADPH-
generating isocitrate dehydrogenase reaction of the TCA cycle, while the 
carbon flux through the glyoxylate pathway was decreased in comparison to 
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wild type E. coli. Further, absolute levels of TCA cycle intermediates were 
generally higher in the mutant than the wild type. Finally, the mutant also 
exhibited a decreased flux through the NADPH consuming methylglyoxal 
pathway, an offshoot of glycolysis, which was inferred indirectly from an 
imbalance of unlabeled and doubly labeled extracellular lactate. The data 
support the utility of RR-IP-LC-MS/MS in the rapid and simple screening for 
alterations in flux distributions in the central carbon metabolism. It does not 
require any prior information on the biological system of interest and, 
therefore, can be applied to any prokaryotic or eukaryotic cell. 
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18 Zusammenfassung 
Die umfassende Analyse aller kleinen Moleküle eines biologischen Systems, 
genannt Metabolomics, kann derzeit nur durch die Kombination von mehreren 
unterschiedlichen analytischen Methoden erfolgen. In der vorliegenden Arbeit 
werden zwei Strategien in diesem Kontext vorgestellt. Eine Methode 
basierend auf Kapillarelektrophorese – Massenspektrometrie wurde für die 
quantitative Analyse von anionischen Metaboliten entwickelt und validiert. Als 
besonders vorteilhaft stellte sich die Verwendung eines hochauflösenden 
Flugzeitmassenspektrometers dar, wodurch die robuste Quantifizierung von 
ausgewählten bekannten Metaboliten mit automatisierter Detektion von  
zusätzlichen potentiellen Metaboliten und anschließender Datenbanksuche 
verbunden werden konnte. Die Methode wurde zur Untersuchung von 
metabolischen Veränderungen unter verschiedenen Wachstumsbedingungen 
in der Escherichia coli Deletionsmutante UdhA-PntAB, in welcher beide 
Nikotinamidnukleotid-Transhydrogenasen fehlen, eingesetzt. Durch die gleich-
zeitige Analyse der Proben mit zwei verschiedenen Gaschromatographie – 
Massenspektrometrie basierten Methoden, konnte zum einen eine 
Vergleichsprüfung der quantitativen Ergebnisse erfolgen, zum anderen konnte 
auch eine umfassendere Abdeckung des E. coli Metaboloms erzielt werden. 
Des weiteren wurde eine Methode basierend auf Ionenpaar – Flüssigkeits-
chromatographie gekoppelt mit einem Tandemmassenspektrometer entwickelt 
und für die Analyse der Isotopomerenverteilung in Intermediaten des 
gesamten zentralen Kohlenstoffstoffwechsels, i.e. Glykolyse, PPP, TCA und 
davon abzweigende Stoffwechselwege,  eingesetzt. Dafür wurden Zellen 
verwendet, welche in Nährmedien inkubiert wurden, die mit [1,2-13C2]Glukose 
supplementiert worden waren. Zusätzlich konnten mit dieser Methode 
ausgewählte Metaboliten mit Hilfe von isotopenmarkierten internen Standards 
zuverlässig und genau quantifiziert werden. Die Methode wurde auf ihre 
Anwendbarkeit getestet, indem die Isotopomerenverteilung innerhalb des 
zentralen Kohlenstoffstoffwechsels in den beiden oben genannten E. coli 
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Stämmen gemessen wurde. In der Mutante konnte eine Verschiebung der 
Stoffwechselflüsse in Richtung des oxidativen PPP beobachtet werden, was 
sehr gut mit publizierten GC-MS Daten korrelierte. Außerdem wurde in der 
Mutante ein relativer Anstieg des Flusses durch den Isozitrat-Dehydrogenase 
katalysierten Teil des Zitratzyklus beobachtet, im Zuge dessen auch NADPH 
generiert wird, während der Fluss durch den Glyoxylatweg im Vergleich zum 
Wildtyp verringert war. Des weiteren wurden in der Mutante zumeist höhere 
Konzentrationen an Zitratzyklus-Intermediaten gefunden. Schließlich zeigte 
die Mutante zudem einen verringerten Fluss durch den Methylglyoxalweg, in 
welchem NADPH verbraucht wird und welcher einen Seitenweg zur Glykolyse 
darstellt. Diese Daten unterlegen die Eignung der entwickelten Methode als 
schnelle und einfache Strategie für das Screening von Veränderungen in den 
Flüssen des zentralen Kohlenstoffstoffwechsels. Man benötigt dafür keinerlei  
vorausgehende Informationen über das untersuchte biologische System, 
weshalb die Methode auf jede prokaryotische oder eukaryotische Zelle 
angewendet werden kann.  
 
 
 
 
